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ABSTRACT 
 Vaccines are credited with saving millions of lives, yet there still remain 
infectious diseases with no effective vaccine. Subunit vaccines contain specific 
components from pathogens, which, cannot stimulate the immune system alone, 
necessitating the inclusion of an immunostimulatory adjuvant. Toll-like receptor (TLR) 
ligands, due to their immunostimulating ability are being explored as potential adjuvants. 
To further advance vaccine development, thorough investigations need to be performed 
to characterize cellular interactions within the immune system after stimulation and how 
adjuvants affect this process including antigen distribution within the draining lymph 
node.  Our studies have focused on a TLR2/TLR1-ligand based adjuvant, PorB, the major 
outer membrane protein from Neisseria meningitidis. We hypothesized that TLR 
adjuvants would increase antigen deposition onto follicular dendritic cells (FDC) which 
would enhance high affinity antibody production and that depletion or knockouts of 
subcapsular sinus CD169+ macrophages would negatively affect antibody production. We 
demonstrated that PorB increased FDC frequency and antigen deposition on these FDCs. 
Further studies examined the role of CD169+ macrophages in PorB adjuvanticity using 
		 x 
low-dose clodronate treated mice (which preferentially removes CD169+ macrophages), 
or CD169 knockout mice. Compared to wildtype controls, low-dose clodronate mice and 
CD169 knockout mice had greatly decreased antibody response with the use or PorB as 
an adjuvant along with decreased antigen deposition on FDCs. Together, these data 
emphasize the effect of adjuvant stimulation on cellular interactions antigen distribution 
in lymph nodes along with the unique ability of PorB to affect this process.   
. 
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CHAPTER ONE- INTRODUCTION 
Vaccines 
Global Advantages of Vaccines 
 Vaccines are arguably the greatest achievement in medicine. Infectious 
diseases have been present throughout human history. Smallpox (Variola major and 
Variola minor) can be found in Egyptian mummies (Prevention, 2016). The plague 
(Yersinia pestis) killed approximately 60% of the population of Europe in the 1300s 
(Schmid et al., 2015). One of the first infectious disease scientists was Girolamo 
Fracastoro (1483-1553). He hypothesized that certain diseases were caused by specific 
invisible organisms (Howard-Jones, 1977). It was not until the later invention of the 
microscope and subsequent studies of microbiology that numerous scientific studies of 
disease etiologies occurred. These studies paved the way for the dawn of vaccinology as 
a science, which can be traced to Edward Jenner’s empirical study of the protection 
conferred against smallpox by cowpox. Jenner’s work introduced the scientific field of 
vaccines, a topic intimately entwined with immunology.  
Edward Jenner was an Englishman who began studying medicine at the age of 
thirteen (Riedel, 2005) in 1762. During this time, the current method to prevent the 
spread of smallpox was inoculation, which involved scabs or “matter” from a smallpox 
patient being placed into a wound created by a doctor, after which the recipient would be 
isolated from the general public for 10 days to a month (Willis, 1997). Although 
inoculation was substantially safer than contracting smallpox disease, which carried a 
death rate of ~20%, the rates of death due to inoculation were still ~2% (Morgan & 
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Parker, 2007). So, Jenner sought to find another method of protection with a lower death 
rate. It had been observed that dairymaids who had contracted cowpox were subsequently 
protected from smallpox, and this finding led Jenner to question the current inoculation 
methods. Jenner hypothesized that inoculation with cowpox, a less severe disease than 
smallpox, would be a safer means of providing protection against smallpox. In 1796, 
Jenner exposed an 8-year-old boy to “matter” isolated from a dairymaid who had recently 
been infected with cowpox (Riedel, 2005). The boy showed mild signs of infection, 
including low fever and loss of appetite. One month later, Jenner inoculated the boy with 
matter from a smallpox lesion, and the boy was protected (Riedel, 2005).  While other 
people had performed inoculation using smallpox lesions prior to Jenner’s study (Barquet 
& Domingo, 1997; Langer, 1976), the importance of eliciting protection by inoculating 
with a weaker disease cannot be understated. Jenner’s studies led to great progress in the 
field of microbiology and could be said to be the start of the disciplines of vaccinology 
and immunology.  
Jenner’s studies led a global shift for protection the public from smallpox from 
inoculation to vaccination with cowpox. Consequently, throughout the 18th and 19th 
centuries, many scientists spent their careers investigating infectious diseases and how to 
prevent global spread of these diseases (Blevins & Bronze, 2010; Rietschel & Cavaillon, 
2002; Smith, 2012; Ullmann, 2007). These studies led to directed improvement of 
vaccinations and vaccine regimes, leading to the eradication of smallpox in 1980 (Fenner, 
1982), which, in the United States alone, is said to save approximately 1 billion dollars 
annually (Nelson, 1999). Vaccinations have also significantly decreased the global 
		
3 
implications of other diseases. According to the United Nations Children’s Fund 
(UNICEF), in 2017 90% of children, worldwide, are protected from Diphtheria, 64% are 
protected from whooping cough, and 84% are protected from measles, because of 
increase in the availability of vaccinations (UNICEF, 2018a). While these numbers are 
impressive, it is still vital to continuously vaccinate the newer generation to these 
infectious diseases for multiple reasons. 
 “Herd immunity” can be defined in multiple ways, but the most common 
definition is the number of people within a population that need to have protection from a 
certain disease in order to prevent further infections from occurring in non-immune 
individuals (Fine, Eames, & Heymann, 2011). This theory is pivotal, not only for very 
infectious diseases, but also for people who are immunocompromised and therefore more 
susceptible to normally sub-lethal infections. Measles is a virus that is incredibly 
infectious. In the first 3 months of 2019, measles infections were 300% more frequent 
globally than they had been over the same time period in 2018 (WHO, 2019). Currently, 
the Centers for Disease Control and Prevention (CDC) reports that 90% of the population 
surrounding one infected person would need to be protected for measles to remain 
contained to only that one person (CDC, 2016). This containment is critical for the 
general public, but is even more so for people who are immunocompromised for any 
reason. Cancer patients, those infected with human immunodeficiency virus (HIV) or 
diabetics can all have immune systems that are inadequate for protection against 
infectious diseases (Klugman, Madhi, & Feldman, 2007; Petridou et al., 2001; Rewers & 
Ludvigsson, 2016). Vaccines play a central role in providing herd immunity; by 
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providing direct protection to those who are able to be vaccinated and indirectly protect 
those individuals who are unable to receive a vaccine.  
The early work of Edward Jenner and other early scientists dramatically shifted 
the fields of microbiology and immunology. Together, these branches of study comprise 
the field of vaccinology. Because of vaccinations, smallpox has been globally eradicated, 
and other diseases have been significantly decreased. It is critical to maintain 
vaccinations for these diseases in order to achieve complete eradication where possible. 
Researchers also need to continue to examine the immune system to develop efficient 
vaccines for diseases that still lack them. While the story of smallpox is one of great 
victory, there also remain many diseases today without efficient vaccines. 
Infectious Disease Currently 
Despite the impressive public health strides made by the introduction of 
vaccinations, many infectious diseases still persist in the world today. Four of the most 
prevalent such diseases are malaria, HIV, acute respiratory infections, and viral 
hemorrhagic fevers (Ericsson, Steffen, & Isaäcson, 2001; Falzarano & Feldmann, 2013; 
Fauci et al., 2008; "Global Statistics | HIV.gov," ; Monto & Lehmann, 1998; 
Organization, 2019b, 2019c; Simoes et al., 2006; UNICEF, 2018b; Walker & Burton, 
2008). While some of these diseases can be classified as “rare”, they have global 
implications. The costs in terms of human life and resources for these diseases, especially 
HIV and malaria, motivate many individuals in the field of vaccine research to hunt for 
new vaccine candidates (Ballou & Cohen, 2013; Durier et al., 2006).  
 Human immunodeficiency virus (HIV) is a retrovirus that integrates its viral 
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genome into the host genome of an infected cell (Douek, Roederer, & Koup, 2009; 
Weiss, 1993). HIV identifies target cells through recognition of extracellular proteins, 
CCR5 (Huang et al., 1996) and CXCR4 (Doranz et al., 1997; Lu et al., 1997), which are 
coreceptors most commonly expressed on CD4+ T cells (Bleul, Wu, Hoxie, Springer, & 
Mackay, 1997). The subsequent viral infection of these specifically targeted cells is how 
HIV causes depletion of CD4+ T cells, leading to a decrease in the immune system’s 
ability to protect the individual, which is known as Acquired Immunodeficiency 
Syndrome (AIDS) (Blattner, Gallo, & Temin, 1988; Weiss, 1993). In 2017, 36.9 million 
people worldwide, 1.8 million of which were children, were infected with HIV and 
940,000 people died from the disease (UNAIDS, 2019). Anti-retroviral therapies (ART), 
the current therapeutics for HIV, target various stages of the viral replication cycle (Alvi, 
Khalique, Ahmad, Khan, & Faizi, 2019; Autran et al., 1997). Consequently, ART 
treatments slow disease progression by slowing viral replication. Despite all recent 
efforts, the infection rate of HIV has only dropped 16% since 2010 (UNAIDS, 2019). 
While ART has extended the average lifespan of infected individuals (Johnson et al., 
2016; Katz & Maughan-Brown, 2017), an HIV vaccine is still desired in order to prevent 
infection completely (Burton, 2019; Fauci et al., 2008). One promising vaccine candidate, 
VCP1521 + AIDSVAXB/E, has shown a slight and significant reduction of HIV 
infection in humans (Rerks-Ngarm et al., 2009). This vaccine uses a recombinant virus 
that expresses HIV proteins in order to generate immune protection against these specific 
proteins. There are also two boosters that consist of the HIV envelope protein, GP120. 
Unfortunately, the results of trials using this vaccine are still debated among experts in 
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the field (Gilbert et al., 2011; Zolla-Pazner & Gilbert, 2019). In order to eradicate the 
world of HIV, a vaccine against HIV would be the most beneficial.  
Malaria is another infectious disease that has worldwide implications, especially 
in developing countries. In 2016, 90% of malarial deaths were in African regions 
(Organization, 2019b; UNICEF, 2018b). In 2017, 219 million cases of malaria were 
estimated to have occurred, which was an increase from the previous year (Organization, 
2019b).  Malaria is an infection with a Plasmodium parasite that targets red blood cells 
and can lead to death if untreated. There are two main Plasmodium species that cause 
malaria: Plasmodium falciparum and Plasmodium vivax (Hall et al., 2005). The current 
treatment for malaria is artemisinin-based combination therapy (ACT), which targets the 
plasmodium within the red blood cell during the reproductive phase of the parasite to 
prevent further transmission (Attaran et al., 2004; Eastman & Fidock, 2009; Maslove et 
al., 2009). While ACT has been a vital therapeutic for malaria, resistance to these drugs is 
increasingly prevalent in African and Asian countries (Naß & Efferth, 2019). A recent 
vaccine candidate, RTS,S/AS01, showed promising results for preventing initial 
infections. This vaccine consisted of a genetically modified hepatitis virus vector 
engineered to express conserved surface proteins of P. falciparum along with an adjuvant 
(Rts et al., 2011; Vekemans et al., 2011). Unfortunately, this vaccine was not shown to 
provide protection over a 7-year period (Olotu et al., 2016) after injection. As the main 
populations affected by malaria infection are children under five years of age and 
pregnant women (Organization, 2019b), the development of a vaccine to prevent 
transmission is imperative. A recent review article highlighted the dire need for such a 
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vaccine (Pance, 2019).  
Although infectious diseases have been present throughout human history, the 
number of infections is currently on the rise despite modern medical advancements (K. F. 
Smith et al., 2014). The recent outbreaks of Ebola virus disease garnered worldwide 
attention due to the high fatality rate among those infected (~50%, (Organization, 
2019a)). Ebola is an enveloped, non-segmented, negative sense, single-stranded RNA 
virus (Kiley, Regnery, & Johnson, 1980; Regnery, Johnson, & Kiley, 1980). 
Unfortunately, because of the high fatality rate of Ebola, the pathogenesis of the virus has 
not been well studied. Currently, the rVSAV-ZEBOV vaccine is showing promising 
results in non-human primates (Ledgerwood et al., 2017) and in phase I clinical trials 
(Regules et al., 2017). This vaccine utilizes a genetically modified virus to express the 
Ebola virus glycoproteins and elicit an adaptive immune response against Ebola. 
Vaccination prior to exposure would elicit specific antibody (Ab) responses to Ebola and 
therefore prevent systemic infection. Although the initial results from this vaccine 
candidate are promising for prevention of this very deadly disease, more studies need to 
be in the pipeline to ensure that an effective vaccine is developed prior to the next 
outbreak. 
Vaccines have changed the way physicians approach infectious diseases. Edward 
Jenner, though not the first to utilize inoculation, propelled the field of microbiology 
forward by bringing focus on the importance of vaccinations and consequently 
immunology. The eradication of smallpox and the significant decreases in measles 
emphasizes how vaccinations can improve global health. Unfortunately, numbers of 
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infectious disease cases are increasing as new diseases emerge. The continuous threat of 
infectious diseases without effective vaccines underscores the need for a more thorough 
understanding of immune system dynamics in terms of both how to stimulate optimal 
immunity and what cellular interactions underlie different immune responses. 
Adjuvants 
History of Adjuvants 
The work done by Jenner and others inevitably increased the number of scientific 
studies focused on infectious diseases. A majority of the early successful vaccines, 
including the smallpox vaccine, were mostly developed by empirical design (Prevention, 
2018; Riedel, 2005). While these successes should not be diminished, the lack of 
effective vaccines for a multitude of other diseases challenges vaccine development and 
researchers today to expand from the use of attenuated pathogens to more targeted 
approaches using the immune system (Di Pasquale, Preiss, Tavares Da Silva, & Garçon, 
2015; Gutierrez, Spero, Gay, Zimic, & De Groot, 2012; Kaufmann, Fensterle, & Hess, 
1999; Moyle & Toth, 2013; Rueckert & Guzmán, 2012). Studies of such approaches 
provide twice as much information as empirical techniques, as their results can lead to 
both a greater understanding of the immune system and the ability to create new 
vaccines.  
Vaccine development has paralleled advances in microbiology and immunology. 
Microbiological studies have revealed specific proteins of bacteria and viruses that can be 
targeted to prevent further infection and would therefore be ideal proteins to elicit 
vaccine-induced immunity against (Plotkin, 2003). These proteins on their own, however, 
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are not able to sufficiently stimulate the immune system to generate protection. To make 
use of these protective epitopes, another molecule must be used to stimulate the immune 
system. Charles Janeway Jr., a major contributor to the field of immunology, described a 
“dirty little secret” that is present within attenuated pathogens or relatively impure 
vaccines, unbeknownst to prior scientists. His work was pivotal to the development of 
adjuvants and to understanding the interactions between the innate and adaptive immune 
systems.  
The “dirty secret” that Janeway had discovered was that of pathogens associated 
molecules that trigger signaling through host pattern recognition cell receptors (Janeway, 
1989). Pathogen associated molecular patterns (PAMPs) are conserved regions on 
molecules present in pathogens that are never or rarely present on eukaryotic cells and 
rarely vary between a certain group of these pathogens and (Gust et al., 2007; Nurnberger 
& Brunner, 2002). PAMPs signal to host cells that the molecule is not self (Janeway & 
Medzhitov, 2002) and therefore needs to be removed. Examples of PAMPs include 
molecules within bacterial walls, lipopolysaccharide, microbial glycoproteins, the flagella 
of bacteria, double stranded RNA, single stranded RNA, and other conserved amino acid 
constructs (Akira, 2006; Ross, 2000; K. Stern & Lein, 2001). PAMPs must interact with 
host cells for intercellular signaling. Pattern recognition receptors (PRRs) have been 
determined to be the receptors for many PAMPs and therefore mediate clearance of the 
“non-self” molecule. PRRs are encoded in the germline of host cells and are highly 
expressed on immune cells (Gordon, 2002). One subset of PRRs are called Toll-like 
Receptors (TLRs) (Akira & Hemmi, 2003; Armant & Fenton, 2002).  
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Toll-like Receptor Ligand Based Adjuvants 
TOLL-like receptors (TLR) were originally described in drosophila (first named TOLL 
receptors) and have since been shown to be a very well conserved receptor family 
(Armant & Fenton, 2002). Currently, 12 TLRs have been discovered in mice, while 10 
have been discovered in humans (Rehli, 2002). TLRs can be extracellular or intracellular 
(Akira & Takeda, 2004; Chaturvedi & Pierce, 2009). Extracellular TLR activation has 
been shown to signal through the cofactors myeloid differentiation primary response 
factor 88 (MyD88) and tumor necrosis factor receptor-associated factor 6 (TRAF6) 
(Yamamoto & Takeda, 2010) to increase proinflammatory cytokine production (Liu & 
Ding, 2016). TLRs 1, 2, 4, 5 and 6 are all extracellular TLRs (Chaturvedi & Pierce, 
2009). Intracellular TLR activation has been shown to signal through either MyD88  or 
another co-factor, TIR-domain-containing adapter-inducing interferon-β (TRIF) (Akira, 
2006), leading to an increase in type I interferons (Liu & Ding, 2016). TLRs 3, 7/8, and 9 
are endosomal TLRs (Chaturvedi & Pierce, 2009). The differences in intracellular 
signaling between various TLRs have been very well characterized in multiple innate 
immune cells (Figure 1.1) (Caron et al., 2005; Gibson et al., 2002; Jack et al., 2005; 
Moore, McCarthy, & Mills, 1999; van Haren et al., 2016).  	
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Figure 1.1: TLR Intracellular Signaling 	
Innate immune cells, including dendritic cells and macrophages, are able to skew 
the adaptive (memory) T and B cell immune responses towards inflammatory/cytotoxic 
(Th1/Th17) or immunoregulatory/suppressive (Th2) effector function profiles (Fearon & 
Locksley, 1996), investigators began to utilize TLR-ligands as an adjuvant, or 
immunostimulator, for subunit vaccines in order to increase vaccine safety (S. G. Reed, 
Hsu, Carter, & Orr, 2016; Steven G. Reed, Orr, & Fox, 2013; Rharbaoui et al., 2002; 
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Vasou, Sultanoglu, Goodbourn, Randall, & Kostrikis, 2017). Extracellular TLR-ligand 
based adjuvants are well known to skew adaptive immunity towards a Th2 response in 
vivo (Beutler, 2009; Platt, MacLeod, Massari, Liu, & Wetzler, 2013), whereas 
intracellular TLR-ligand based adjuvants have shown to increase Th1 adaptive immunity 
and protection (Averett, Fletcher, Li, Webber, & Appleman, 2007; Deres, Schild, 
Wiesmuller, Jung, & Rammensee, 1989; Pulko et al., 2009). It is thought that TLR-ligand 
based adjuvants will greatly improve vaccine design of the future (Gutjahr, Tiraby, 
Perouzel, Verrier, & Paul, 2016; Lambrecht, Kool, Willart, & Hammad, 2009; McKee & 
Marrack, 2017; Moyer, Zmolek, & Irvine, 2016) 
TLR2-ligand Based Adjuvant, PorB 	
A major outer membrane protein isolated from Neisseria meningitidis, PorB, has 
been isolated and studied in Dr. Wetzler’s laboratory for the past 20 years (Massari et al., 
2002). PorB was isolated in our laboratory in the native state, free of other contaminants 
(including other TLR ligands like lipoproteins or lipopolysaccharide) and shown to have 
multiple characteristics desirable for an adjuvant (Massari, King, MacLeod, & Wetzler, 
2005). PorB can induce signaling through TLR1/2 complexes and is dependent on the 
TLR cofactor protein MyD88 (Massari et al., 2006).  Since initial isolation, PorB has also 
been shown to increase co-stimulatory factors in bone marrow derived dendritic cells and 
macrophages (BMDC and BMDM) (Platt et al., 2013; Reiser, Mosaheb, Lisk, Platt, & 
Wetzler, 2017), increase cytokine expression in vitro and in vivo (M. Mosaheb & 
Wetzler, 2018; M. M. Mosaheb, Reiser, & Wetzler, 2017; Platt et al., 2013), increase 
antigen trafficking to draining lymph nodes (Reiser et al., 2017), increase antigen specific 
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immunoglobulins (IgG) production and subtype diversity(M. M. Mosaheb et al., 2017) , 
increase cross-presentation to T cells (Reiser et al., 2017), and increase clearance of an 
intracellular pathogen after vaccinations (M. Mosaheb & Wetzler, 2018). Interestingly, 
PorB has been shown to increase both Th1, Th2, and CD8 antigen specific responses. 
These characteristics are desirable endpoint goals in adjuvant development (Awate, 
Babiuk, & Mutwiri, 2013). Together, these data emphasize how PorB as an adjuvant is 
able to stimulate innate immune cells as well as influence both cellular and humoral 
adaptive immunity to a specific antigen. 
TLR9-ligand Based Adjuvant, CpG 	
To determine the role of intracellular TLR signaling in this thesis, synthetic 
oligodeoxynucleotides (ODNs) with unmethylated CpG motifs were utilized. These 
motifs are conserved within bacterial DNA but are rare in eukaryotic DNA (Krieg, 2002). 
CpG has been widely studied in the adjuvant field (Bode, Zhao, Steinhagen, Kinjo, & 
Klinman, 2011; Chu, Targoni, Krieg, Lehmann, & Harding, 1997; D. M. Klinman, 
Klaschik, Sato, & Tross, 2009; D. M. Klinman, Xie, Little, Currie, & Ivins, 2004; Tross 
& Klinman, 2008). It has been shown to increase innate immune expression of cytokines 
(Agren, Thiemermann C Fau - Foster, Foster Sj Fau - Wang, Wang Je Fau - Aasen, & 
Aasen; Lehtimäki, Lauerma, Wolff, & Alenius, 2004; Sun, Zhang, Tough, & Sprent, 
1998), increase antigen specific antibodies (Dennis M. Klinman, 2006; D. M. Klinman et 
al., 2009; McCluskie, Weeratna, Krieg, & Davis, 2000), and increase Th1 adaptive 
immune responses (Chu et al., 1997; Gierynska et al., 2002; Hoft, Eickhoff, Giddings, 
Vasconcelos, & Rodrigues, 2007; B. V. Stern, Boehm, & Tary-Lehmann, 2002). CpG has 
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also been used in clinical trials, most recently within a vaccine for melanoma (Koster et 
al., 2017). CpG has been shown to be more targeted to Th1 adaptive responses alone 
whereas PorB has been shown to increase both Th1 and Th2 responses. Therefore, the 
inclusion of CpG as a comparator adjuvant in these studies allows investigation of 
different cellular pathways and cellular interactions within lymph nodes.   
Aluminum Salts (Alum) 
Since 1926, aluminum salts (Alum) has been the most prevalent adjuvant used in 
vaccines, although the mechanism of action is still not fully understood (Marrack, 
McKee, & Munks, 2009). Intracellularly, Alum has been shown to signal through the 
Nlrp3 inflammasome, activating caspase-1 (Franchi & Núñez, 2008). It has also been 
shown that Alum forms an antigen depot at the site of injection allowing for a slower 
exposure to the antigen over days (Gupta, 1998; Lindblad & Schonberg, 2010; 
Rajananthanan, Attard, Sheikh, & Morrow, 1999). This deposition allows for more innate 
immune cells to have access to antigen over days, thereby allowing for more antigen to 
be trafficked to the lymph nodes.  The inclusion of Alum in vaccines has been shown to 
increase chemokines at the site of injection allowing for increased innate immune cell 
infiltration (Lambrecht et al., 2009). Vaccines including Alum have also been shown to 
elicit significant increases in antigen specific antibodies (Gupta, 1998; Gupta, Rost, 
Relyveld, & Siber, 1995; Iyer, HogenEsch, & Hem, 2003). While vaccines including 
Alum generate very high numbers of antibodies, these antibodies may be lacking in 
quality (Francica et al., 2017) and the cellular mechanisms for Alum’s are not well 
defined. Alum was exploited in these studies as a non-TLR adjuvant to better understand 
		
15 
cellular interactions post-vaccination.  
 The discovery of pathogen associated molecular patterns (PAMPs) and pattern 
recognition receptors (PRRs) has led to more targeted vaccine candidates utilizing 
specific epitopes from infectious diseases to reduce incidence and severity of new 
infections (Moyle & Toth, 2013). Because these proteins alone are unable to stimulate the 
immune system, adjuvant research has flourished, with studies aiming not only to provide 
protection but also to tease apart specific cellular interactions occurring within the 
immune system that track with protection. This has led to thorough characterization of 
the intracellular signaling and adaptive responses elicited by the TLR ligand-based class 
of adjuvants. These and other adjuvants have repeatedly been shown to increase antigen 
specific antibody production and, in specific cases, increases in cellular responses as 
well.  
The Immune System 
The Innate Immune System 
Human immunity has been divided into two main systems – the innate system and 
the adaptive system. The innate system is known for quick and unspecific initial reactions 
to invading pathogens (Fearon & Locksley, 1996; Janeway & Medzhitov, 2002; 
Nurnberger & Brunner, 2002), although this concept may be evolving (Boraschi & 
Italiani, 2018). It is well recognized that innate cells are the first cells to respond to 
pathogens (Mueller, 2010). The main innate cells that respond to an infection are 
neutrophils, macrophages, and dendritic cells (DCs). After exposure to antigen, antigen 
presenting cells (APCs) uptake antigen and transport it to either primary or secondary 
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lymphatic tissues (Randolph, Angeli, & Swartz, 2005). Since the studies within this thesis 
focus on initiation of an adaptive immune response within the secondary lymphatic 
organs (SLOs), primary lymphatic tissue will not be discussed. Once antigen arrives to 
the secondary lymphatic tissue, it is either processed for antigen presentation or 
transported to follicular dendritic cells (FDCs), with both processes initiating the adaptive 
immune system.  
Pathogens can enter the body through various routes. In vaccination, a bolus of 
liquid is injected either intramuscularly or subcutaneously. Differences in pressure 
between the tissues can cause a release of pro-inflammatory cytokines and chemokines 
(Strbo, Yin, & Stojadinovic, 2014). These cytokines signal for innate immune cells to 
circulate to the area. Once the innate cells arrive, they secrete more inflammatory 
cytokines (Medzhitov, 2007; Wanke et al., 2011). Infiltration of DCs and macrophages at 
a vaccine injection site is critical event in order to allow for trafficking of antigen and 
therefore the initiation of the adaptive immune responses. One characteristic of adjuvants 
is their ability to increase recruitment of innate cells to the injection site in order to 
increase antigen loaded DCs to the secondary lymphoid organ (SLO) for adaptive 
immune responses (Awate et al., 2013). Once the innate cells are present, adjuvants have 
also been shown to increase antigen uptake by APCs (Steven G. Reed et al., 2013; Reiser 
et al., 2017). An increase in APC exposure to antigen and/or more antigen uptake in the 
APCs will lead to more antigen within the lymph node for adaptive immune responses 
which could lead to better protection from the adaptive immune system, less 
immunizations, or less antigen needed for vaccinations (Steven G. Reed et al., 2013) 
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which are two key characteristics of adjuvants. 
Antigen Trafficking in the Innate Immune System 
Inducing antigen trafficking to the SLO is a characteristic of optimal adjuvants (Awate et 
al., 2013). One way for antigen to be trafficked from the injection site to the SLO if via 
APCs, especially DCs (Randolph et al., 2005; Tomura et al., 2014). Adjuvants, including 
PorB, have been shown to increase the amount of DCs loaded with antigen in the 
draining lymph node after injection (Reiser et al., 2017). Free antigen can also reach the 
SLO via the lymphatic vessels (Sixt et al., 2005). The distribution of free antigen, once it 
has arrived at the SLO, has been closely tied to antigen size (Hirosue & Dubrot, 2015).  
Small molecules (<70kDa) have three main fates once arriving at the SLO. Stromal cells 
surrounding the subcapsular sinus (SCS) will pick up and retain soluble free antigen 
(Pape, Catron, Itano, & Jenkins, 2007). Other antigens will slip through the SCS via 
proteins known as plasmalemma vesicle-associated proteins (Hirosue & Dubrot, 2015), 
leading to direct contact with follicular dendritic cells (Bajénoff & Germain, 2009). 
Lastly, small antigens can leave the lymph node via high endothelial venules (Gretz, 
Norbury, Anderson, Proudfoot, & Shaw, 2000). Larger antigens and immune complexes 
– antibody bound to antigen – can be sampled through macrophages lining the SCS 
(Grabowska, Lopez-Venegas, Affandi, & den Haan, 2018; Martinez-Pomares & Gordon, 
2012; Tri Giang Phan, Green, Gray, Xu, & Cyster, 2009). If not sampled by the SCS 
macrophages, these antigens will move to the next lymph node via the medullary sinus. 
Near the medullary sinus, however, there are resident DCs that can sample the lymph and 
can present antigen to T cells (Gerner, Torabi-Parizi, & Germain, 2015) prior to exiting 
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the lymph node. Few studies have compared how different adjuvants influence these 
pathways (Piccioli et al., 2019). Whether antigen arrives in the SLO from DCs or freely, 
these events initiate adaptive immune responses in variety of ways.  
As previously mentioned, trafficking DCs arrive in the lymph node with 
processed antigen from the injection site (164). This trafficking requires the expression of 
chemokines from the lymph nodes (Förster, Braun, & Worbs, 2012). DCs then use the 
processed antigen peptide on MHC as the first signal for cognate T cell activation 
(Goenka et al., 2011) which requires three signals for complete activation (Cronin & 
Penninger, 2007). The second signal is co-stimulatory factors on the DC (McLellan, 
Heiser, & Hart, 1999). The final signal is cytokine expression near the T cell (da Silva et 
al., 2013). These three signals are imperative for full T cell activation. One desirable 
characteristic of an adjuvant is to increase all three of these signals from DCs to 
expediate the T-cell responses once DCs arrive from the injection site (Awate et al., 
2013). It is important to note that DCs can cross-present to both CD4+ and CD8+ T-cells 
(Belz, Carbone, & Heath, 2002) via MHC II or MHC I (DeKoning, Carbone, & Kaye, 
1995). This makes for another interesting characteristic of adjuvants – the ability to 
activate both CD4+ and CD8+(M. Mosaheb & Wetzler, 2018; Welters et al., 2007).  CD4+ 
T cells in SLOs, generally known as T follicular helper cells (Tfh), are essential for B cell 
activation and differentiation into plasma cells and memory B cells (Crotty, 2014). The 
precise mechanism of how B cells differentiate is still unknown, but it is thought that 
adjuvants may be able to influence this dynamic process with an end goal of more plasma 
cells and/or memory B cells being created to provide long term protection ("Chapter 14 - 
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B Cell Memory and Plasma Cell Development," 2015; Wang & Bhattacharya, 2014). 
Follicular Dendritic Cell Networks Influence Germinal Center B Cell Fate 
The complete dynamics by which plasma cells and memory B cells are 
differentiated still remains to be fully understood ("Chapter 14 - B Cell Memory and 
Plasma Cell Development," 2015). There is also a need to fully understand how somatic 
hypermutation (SHM) (Pilzecker & Jacobs, 2019; Schramm & Douek, 2018) and affinity 
maturation (Mishra & Mariuzza, 2018; Tabasinezhad et al., 2019) occur within the 
germinal center. This knowledge could greatly impact vaccine design. The events leading 
up to differentiation and SHM, however, have been partially described (Mesin, Ersching, 
& Victora, 2016). Full antigens, in combination with cognate antibodies in the form of 
immune complexes (IC) or as free antigen, are deposited on to follicular dendritic cells 
(Mellors & Brzosko, 1962). FDC are stromal cells within the lymph nodes and spleen 
(Cyster et al., 2000; Krautler et al., 2012). They are located in the light zone of the 
germinal center (Cyster et al., 2000) and are vital for B cell SMH (Cyster & Goodnow, 
1995; Rajewsky, 1996)and possibly B cell differentiation into memory B cells or long-
lived plasma cells (Allen & Cyster, 2008). FDCs receive antigen and IC from the 
subcapsular sinus via SCS macrophages (Tri Giang Phan et al., 2009). Once FDCs 
receive antigen or immune complexes, they retain the entire antigen and recycle it from 
their surface to their cell body in an actin-dependent fashion without proteolytically 
processing the antigen (Heesters et al., 2013). This recycling of whole antigen allows for 
affinity maturation within the light zone of the germinal center and enables the B cell 
receptor to be exposed to the intact antigen (Heesters et al., 2013).  
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The cycle of B cells from the dark zone (DZ) of the germinal center to the light 
zone (LZ) is imperative for optimal antigen specificity of the B cell receptor (BCR) and 
therefore for antibody specificity (Krautler et al., 2017).When B cells enter the LZ and 
are exposed to antigen on the FDC, three outcomes can occur: if there is high affinity 
between the antigen and the BCR, the B cell leaves the germinal center for systemic 
circulation; if the BCR has moderate affinity for the antigen the B cell will return to the 
DZ for further somatic hypermutation; or if the BCR has low affinity for the antigen, the 
B cell will become apoptotic. This cycling of B cells emphasizes the prominent role of 
antigen deposited on the FDCs. While the discovery of FDC and antigen retention was 
found in the late 1960s (Mellors & Brzosko, 1962), it was not until recently that isolation 
of FDCs from tissue was convincing (Usui et al., 2012). To date, very few studies have 
investigated how adjuvants influence follicular dendritic cells and the surrounding 
network (Rocco Cantisani et al., 2015; R. Cantisani & Piccioli, 2015).  
Subcapsular Sinus Macrophages 
To further elucidate the antibody production pathway, our laboratory recently 
investigated which APC was essential for antibody production, specifically when using 
TLR-ligand based adjuvants, particularly the TLR2 ligand PorB. Disrupting TLR2-
signaling was accomplished by breeding a floxed MyD88 (a prominent co-factor in TLR 
signaling) mouse with various cell specific Cre mice – CD19-Cre recombinase for B 
cells, CD11c-Cre recombinase for DCs, and Lysm-Cre recombinase for macrophages. 
When the MyD88-floxed mice are bred with cell specific Cre mice, the recombinase 
protein is transcribed and removes the floxed portion of the gene, in this case removing 
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MyD88 during transcription and preventing translation of MyD88 (Gu, Zou, & 
Rajewsky, 1993). These studies showed that ablation of TLR2 signaling separately in 
each individual type of APC led to significant decreases in antigen-specific antibodies 
normally induced by PorB/Antigen (Ovalbumin) immunizations, with the most dramatic 
drop in animals that lacked MyD88 within macrophages (M. M. Mosaheb et al., 2017). It 
was unexpected that the loss of signaling in macrophages could not be saved by 
functional TLR signaling in DCs. It has not been determined which subtype of 
macrophages could be vital for antibody production, however, one interesting subset of 
macrophages are subcapsular sinus (SCS) macrophages.  
SCS macrophages of the lymph node and marginal zone macrophages of the 
spleen have been described as phenotypically similar (Grabowska et al., 2018) and are 
commonly identified by their expression of CD169. CD169 is an extracellular protein 
that contains no known intracellular signaling pathways (Klaas & Crocker, 2012). The 
structure consists of 1 variable immunoglobin domain and 16 constant immunoglobin 
domains (Crocker et al., 1994). CD169+ macrophages transport antigen and immune 
complexes from the lymph through the cell body without processing the antigen, a unique 
property for macrophages, which are typically known for phagocytosis (Tri Giang Phan 
et al., 2009). Germinal center B cell fate determination begins by deposition of antigen 
and immune complexes onto FDCs via non-cognate B cells (Kranich & Krautler, 2016). 
SCS macrophages have been implicated in multiple studies to have several prominent 
subsequent roles in antibody production (and therefore germinal center B cell fate) 
(Desbien et al., 2016). First, SCS macrophages can extract antigen and retain immune 
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complexes from the lymph, transporting them to the lymph node (Tri Giang Phan et al., 
2009; T. G. Phan, Grigorova, Okada, & Cyster, 2007; Szakal, Holmes, & Tew, 1983). 
The antigen can then activate either the humoral adaptive immune response, leading to 
antibody production (Tri Giang Phan et al., 2009), or activate the cellular adaptive 
response, leading to CD8+ T cell activation (Asano et al., 2011; Bernhard, Ried, 
Kochanek, & Brocker, 2015; Habbeddine et al., 2017). The combination of location and 
cellular properties have led to these cells being described as the “gate keepers” of the 
SLO (Ludewig & Cervantes-Barragan, 2011; Martinez-Pomares & Gordon, 2012).  
Overall, the innate immune system is the first protective immune barrier against infection 
within the human body. Once an inflammatory environment has been created by a 
vaccine or tissue damage and/or, macrophages and DCs will circulate to the area. 
Macrophages will attempt to phagocytose pathogens infections while, DCs will uptake 
the antigen for processing and trafficking to SLOs. Once within the SLO, DCs will 
present processed antigen to activate T-cells. Free antigen can also reach the SLO and is 
then distributed based on the size of the particle. One pathway antigen can take is through 
the SCS macrophages to FDC deposition in the native form. Antigen deposition onto 
FDCs is a critical step in the determination of B cell germinal center fates and possibly 
for differentiation to long lived plasma cells and memory B cells. The adaptive immune 
system cannot function without the innate immune system. Adjuvants have been shown 
to influence innate cell recruitment to the injection site, to increase antigen within DCs, to 
increase antigen trafficking to the lymph node, and to increase T cell stimulation by 
costimulatory molecules and cytokine expression. FDC networks and antigen deposition 
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onto FDCs have not been investigated in adjuvant studies. 
Specific Aims and Hypothesis 
 Edward Jenner and Charles Janeway transformed their scientific fields during the 
era in which they lived. Jenner’s inoculations contained the “dirty little secret” that 
Janeway spent a majority of his career elucidating – native molecular patterns on the 
pathogen that stimulated the innate immune system cells (Janeway, 1989; Janeway & 
Medzhitov, 2002). These cells, in turn, activated a longer immune process via the 
adaptive immune system to provide long term protection against the pathogen in the form 
of memory B cells, long lived plasma cells, and antigen-specific T cells (Fearon & 
Locksley, 1996; Janeway & Medzhitov, 2002). These adaptive cell types are the final 
product that vaccinations are trying to achieve (Coffman, Sher, & Seder, 2010; Plotkin, 
2003). While empirically vaccines have had great successes within the infectious disease 
field, there still remain many threatening diseases without an effective vaccine (Katherine 
F. Smith et al., 2014).  
 Charles Janeway and discovery of the “dirty little secret” created new area for 
vaccine development. These studies proved the pivotal role of innate cells in skewing 
adaptive responses towards Th1 or Th2. Adjuvants are the immunostimulatory 
component of subunit vaccines (Moyle & Toth, 2013; Rappuoli, Pizza, Del Giudice, & 
De Gregorio, 2014; Rueckert & Guzmán, 2012). Because of the importance of PAMPS 
and PRRs, many adjuvants are PRR ligands, especially for the TLR subset of PRRs (Jack 
et al., 2005; S. G. Reed et al., 2016). Adjuvants have the ability to influence adaptive 
immune responses based on the effects on innate cells. This has been shown by our 
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laboratory and others (Awate et al., 2013; McKee & Marrack, 2017; M. M. Mosaheb et 
al., 2017). These studies have progressed the vaccine development and immunology 
fields further, yet there are still cellular interactions and kinetics within the immune 
system that require a fuller understanding in terms of the exact mechanisms occurring 
during an immune response.  
A major end point for an effect vaccine, and therefore a successful adjuvant, is 
antibody production. In order for antigen specific antibody production to occur, the B cell 
receptor (BCR) must have access to the intact antigen to determine affinity between the 
BCR and the antigen. An initial step for BCR specificity determination is antigen 
deposition onto follicular dendritic cells (FDCs) (Kranich & Krautler, 2016; Moalli et al., 
2015). Prior to antigen deposition onto FDC, it has been shown that SCS, which are 
CD169+, are involved with antigen distribution within the lymph nodes, deposition onto 
FDCs, and antibody production (Tri Giang Phan et al., 2009; T. G. Phan et al., 2007; 
Szakal et al., 1983). Further understanding of how adjuvants influence these pathways 
could lead to better adjuvants for future vaccines. We hypothesized that adjuvants would 
increase antigen deposition onto follicular dendritic cells, enhancing their ability to 
increase antibody production, and that depletion of CD169+ macrophages and global 
CD169 knockout would decrease antibody production after vaccination. We addressed 
this hypothesis with two aims: 
Aim 1:  Examine how adjuvants influence antigen distribution within the lymph nodes, 
including antigen deposition on FDCs.  
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Aim 2: Examine the role of CD169+ subcapsular macrophages in antibody production, 
dendritic cell trafficking, and antigen deposition on FDCs.  
 To explore our hypothesis, we included multiple TLR ligand-based adjuvants and 
a non-TLR ligand adjuvant. The inclusion of an extracellular TLR ligand-based adjuvant 
(PorB), an intracellular TLR ligand-based adjuvant (CpG), and a TLR-independent 
adjuvant (Alum) optimizes the information about the cellular dynamics with the draining 
lymph node obtained in these studies. To interrogate the role of the SCS macrophages in 
adjuvant effects on FDCs antigen deposition and antibody production, three animal 
models were used. C57/BL6 mice were used as wild type controls and received the same 
vaccine compositions as the other animal models. Clodronate liposomes are known to 
cause apoptosis of macrophages by being endocytosed and causing a toxic tipping point 
of the drug within the cell (Delemarre, Kors, & van Rooijen, 1990; Jordan, van Rooijen, 
Izui, Kappler, & Marrack, 2003). At lower doses, however, clodronate causes apoptosis 
of CD169+ macrophages specifically (T. L. McGaha, Chen, Ravishankar, van Rooijen, & 
Karlsson, 2011). Low dose clodronate treatment was used to determine the role of 
subcapsular macrophages in responses to different adjuvants in vaccines. Our final 
animal model was a CD169 global knockout. Overall, these studies were designed to 
investigate cellular signaling within the draining lymph node after a subcutaneous 
injection including an adjuvant and what how SCS macrophages influence these signals.  
 The observations made from these studies are described in chapters 3 and 4. With 
an increasing array of infectious diseases threatening the human population, it is 
important to continuously investigate the immune system and work towards new 
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vaccines. Determining the right adjuvant for different scenarios is a key component of 
this process. These studies will provide information about how multiple adjuvants 
influence initial steps for antibody production, including antigen deposition on FDCs, and 
the cellular interactions involving CD169+ cells in these processes.   
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CHAPTER TWO: MATERIAL AND METHODS 
Methods for Chapter Three 
Bone Marrow Derived Macrophages (BMDM) 
 Bone marrow derived macrophages were generated as previously reported (Platt 
et al., 2013). Briefly, C57Bl/6J mice were euthanized and their femurs were cleaned from 
muscle and fur. The femurs were then flushed with PBS using a 25 G needle. To ensure 
erythrocytes were lysed, all samples were incubated with ACK (150 mM NaH4CL, 
50mM KHCO3) buffer for 3 minutes at room temperature. Cells were then strained 
through a 70 µm nylon mesh (ThermoFisher Scientific, USA). Cells were then counted 
and plated at 3x105 cells/plate concentration. RPMI-1640 with 10% FCS (Gibco), 100 
U/mL Penicillin-Streptomycin (Sigma-Aldrich), and 20% L929 was used for the media 
for BMDMs.  On day three, a majority of media was removed (1mL remained) and 
refreshed with 10 mL new media. On day six, cells were counted and plated for 
stimulations. 
Fluorescently Label OVA 
 BMDMs were plated in 96 well plates (Corning) at 105 cells/well and incubated 
overnight in 37°C. Media was then removed and stimulation medias were added to the 
wells. Stimulations were one of the following: media alone, ovalbumin labeled with 
Alexa 594 (OVA-A594, Invitrogen, 5µg/mL), or OVA-A594 + PorB ([OVA] = 5µg/mL, 
[PorB] = 10µg/mL). Cells were stimulated for 0.2, 1, 2, or 3 hours. After the appropriate 
time with stimulus, cells were prepped for flow cytometry.   
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Flow Cytometry For BMDM 
 After stimulation, cells were washed with FACS Buffer and spun down at 300g. 
The supernatant was decanted and the cells resuspend in Fc blocking buffer (1:50 
CD26/CD32, eBioscience, USA) and incubated for 15 minutes in 4°C. Cells were then 
washed and resuspended in the antibody panel. The panel consisted of: CD11c (647, BD 
Pharmigen 50261), CD11b (APC-Cy, BioLegend, Cat#101225), and CD86 (PE-Cy7, 
BioLegend cat #105013). All antibodies were diluted at 1:200 concentration.  
Adjuvants  
PorB was isolated as previously described (Massari et al., 2005). CpG was purchased 
from Invivogen, (Cat# ODN1826). Aluminum salts (alum) was purchased from Sigma 
(Cat# A8222). 
Animals  
Four to eight-week-old female and male C57Bl/6J (referred to as ‘wild type’, stock 
#000664) mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice 
were maintained within the Laboratory Animals Science Center (LASC) at Boston 
University School of Medicine. The Boston University Institutional Animal Care and Use 
Committee (IACUC) approved all research conducted using animal models. 
Murine Immunizations 
Groups of mice received one of the following immunization preparations: 
ovalbumin (OVA) fluorescently labeled with Alexa 594 (OVA-A594) alone (Life 
technologies), OVA-A594 + PorB, OVA-A594 + CpG (Invitrogen, Cat#ODN1826), or 
OVA-A594 + Alum (Sigma, Cat#A8222).  OVA was used at 10 µg per mouse, PorB and 
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CpG at 10 µg per mouse and Alum at 200 µg per mouse based on previous publications 
(M. M. Mosaheb et al., 2017; Platt et al., 2013). An initial kinetic study using OVA-A594 
given alone or with PorB, as above, was performed to determine the optimal time point 
for lymph node isolation to examine effects of adjuvants on antigen deposition on FDCs 
(Figure 2.1). All mice were injected subcutaneously near the base of the tail. Draining 
lymph nodes were isolated after euthanasia 24, 48 or 72 h after immunization (Harrell, 
Iritani, & Ruddell, 2008). The nodes were embedded in optimal cutting temperature 
(OCT) medium (Richard Allan Scientific, Kalamazoo, MI, USA) in molds and used for 
immunohistochemistry. 
Figure 2.1: Experimental Design for Antigen Trafficking within Draining Lymph Nodes. 
Mice were divided into 3 groups – 72 hours, 48 hours, or 24 hours for post injection euthanasia. These 
groups were further divided into OVA-A594 or OVA-A594 + PorB. All injections were subcutaneous. n = 
4/group.   	
Immunohistochemistry 
Draining iliac and inguinal lymph nodes were isolated 24 h after immunization (M. M. 
Mosaheb et al., 2017) and put into molds containing OCT medium and frozen on dry ice. 
Tissues were sectioned on a Microm HM 550 (Microm International GmBH, Germany). 
Vaccines: 
• OVA-A594
• OVA-A594 + PorB
End points: 
•IF
• FDCs 
• OVA-A594
D-3 D0
Vaccinate
Group 1
OVA594 +/- PorB
Sacrifice
All Groups
Figure 2.1: Immunization Schedule for FDC Studies
D-2
Vaccinate
Group 2
OVA594 +/- PorB
D-1
Vaccinate
Group 3
OVA594 +/- PorB
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8 µm sections were obtained and placed on Colorfrost Plus slides and stored at -80°C 
until staining. Sections were air dried for 15 minutes at room temperature, fixed in 
acetone at −20 °C for 10 minutes, and air dried for 10 minutes. Sections were re-hydrated 
in TBS buffer with 0.05% Tween-20 (TBS-T) then blocked for 1 hour at room 
temperature with TBS-T with 5% BSA. Sections were rinsed with PBS and then stained 
with conjugated (CD11c, Biolegend, Cat#117309) and primary (FDC-M1, BD 
Biosciences, Cat#551320) antibodies overnight at 4°C followed by three rinses with PBS. 
Secondary antibody (anti-rat 488, Biolegend, Cat#405418) was added to the slides for 1 h 
at room temperature followed by three washed in PBS. Antibody concentration for the 
primary was 1:100. Conjugated and secondary was used at 1:200 dilution. Stained 
sections were mounted in Fluoroshield mounting medium with DAPI (Abcam), dried 
overnight, and sealed with clear nail polish. A Leica SP5 confocal microscope (Leica 
AG) was used to examine the sections using the Leica LAS AF software using the 10x 
(HC PL FLUORTAR 10.0X0.3 Dry) and 63x oil immersion objectives. All images were 
captured with 4 lines average at 200Hz. The images were arranged and analyzed using 
FIJI/ImageJ (NIH).  
Image Analysis 
After images were obtained from the Lecia SP5 and imported into FIJI/ImageJ 
(NIH). The background was subtracted for each image separately using a rolling ball 
radius of 20.0 pixels. Mean fluorescence intensity (MFI) was determined using the 
ImageJ and the measurement tool. Colocalization between DC or FDC and OVA was 
determined using the JaCoP plugin in ImageJ calculating the Pearson Colocalization 
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Coefficient (Figure 2.2).  
 
To determine the MFI of OVA associated with DC and FDC, Mander’s correlation 
coefficient was determined from the JaCoP plugin as a percentage of OVA (Bolte & 
Cordelieres, 2006) (Figure 2.3) and then multiplied by the total MFI of OVA within the 
lymph node.  
OVA FDC-M1
ImageJ – JaCoP
plugin
Pearson 
Correlation 
coefficients 
Figure 2.2: Quantification of OVA-A594 and FDC-M1
Figure 2.2: Quantification of OVA-A594 and FDC-M1. 
Pearson correlation coefficient analysis. Images were imported into ImageJ and then changed to a 16 bit 
image. The plugin JaCoP was then utilized to determine Pearson correlation coefficient which were then 
calculated for statistical significance in PRISM 8.0 using ordinary one-way ANOVA. 			
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Flow Cytometry of Follicular Dendritic Cells and Dendritic Cells  
Single cell suspensions were created from inguinal lymph nodes 24 hours post 
injection. Briefly, lymph nodes were placed in cold PBS and were manually minced on a 
petri dish with a scalpel. The samples were transferred to a 24-well plate 
(FisherScientific, Cat #08-772-1H), incubated with DMEM containing 2% FBS 
(ThermoFisher, Cat#26140079), 33.3 mg/ml collagenase type IV (ThermoFisher, 
Cat#17104019), and 2500 U/mL DNase I (ThermoFisher, Cat#18047019). Samples were 
incubated for 1 h at 37°C. After which, the samples were strained through 70 µm filter. 
Cells were incubated with a live/dead stain (Biolegend, Cat#423105) for 30 minutes, in 
the dark at 4°C. Cells were then washed with 5x FACS Buffer (PBS, 0.5%BSA, and 2% 
ImageJ –
JaCoP plugin
Mander’s
Correlation 
coefficients 
Figure 2.3: Quantification of Mander’s Correlation Coefficient 
OVA FDC-M1 OVA FDC-M1
OVAFDC-M1
Figure 2.3: Quantification of OVA Distribution within the Draining Lymph Nodes. 
Pearson correlation coefficient analysis. Images were imported into ImageJ and then changed to a 16-bit 
image. The plugin JaCoP was then utilized to determine Manders correlation coefficient. Manders 
correlation coefficients were then analyzed in Prism 8.0 for significance. 
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EDTA) and spun down. Cells were then incubated with CD16/CD32 Fc block 
(eBioscience, 48-0032-82) for 10 minutes in the dark at room temperature. Cells were 
then plated in a 96 V-well bottom plate (Corning, CLS3896-48EA) and stained. All 
dilutions were 1:200. Antibodies included: CD19-BUV395 (BD Horizon, 563557), CD3 
– eFlour  (Invitrogen, 48-0032-82), CD11c – APC (BD Pharmigen, 550261).  Cells  were   
 
 
Figure 2.4: Gating Strategy for Dendritic Cells (DC) and Antigen Loaded DCs. 
A) Gating strategy for DCs in draining lymph nodes. (B) Gating strategy for antigen loaded DCs. Gates 
were created to remove doublets and dead cells. DCs were then selected from CD3- and CD19- gates. 
OVA-A594+ gate was created to determine % of DCs with antigen. (C) Fluorescent minus one gate for 
594+CD11c+ events. An animal injected with PBS is shown in pink. An animal injected with OVA-A594 is 
shown in cyan. These graphs are taken from live CD3-CD19- cells. 
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the analyzed on an LSRII. The gating strategy is shown in Figure 2.4A and B. Animals 
were vaccinated with OVA lacking the Alexa594 fluorochrome as negative controls as 
shown in Figure 2.4C.  
Single cell suspensions for FDCs were performed similarly. The samples were 
strained through 70 um filter, although not pushed through to ensure the integrity of the 
FDCs remained intact. Samples were then stained for live/dead, Fc block, and conjugated 
antibodies. All antibody dilutions were 1:200 unless otherwise noted. CD21/CD35 – 
BV421, CD45 – APC, CD19 – BUV395 (1:400), ICAM-1 – FITC. Gating strategy is 
shown in Figure 2.5A. A fluorescence minus one (FMO) was stained for all colors within 
A.	
B.	
Figure 2.5a: Gating Strat gy for Follicular Dendritic Cells
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Figure 2.5b: Gating Strategy for FDC Cells – FMO for Cr1/Cr2
Sample FMO
SS
C-
A
Cr1/Cr2
SS
C-
A
Cr1/Cr2
Figure 2.5: Gating Strategy for Follicular Dendritic Cells Including Fluorescence Minus One. 
(A) The gating strategy for follicular dendritic cells (FDC). (B) Fluorescence minus one (FMO) for 
Cr1/Cr2. Two samples were analyzed based on the gating strategy in Figure 2.5A. One sample contained 
Cr1/Cr2 antibody (pictured on the left). The other did not (pictured on the right).  
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the panel excluding CD21/CD35 shown in Figure 2.5B. All samples were analyzed on an 
LSRII, a machine available within the Boston University flow core, on a low flow 
setting. 
Study Design for Antigen Deposition on Follicular Dendritic Cells after Second Injection 
Six to eight weeks old female C57Bl/6J (referred to as ‘wild type’, stock #000664) mice 
were obtained from Jackson laboratories (Bar Harbor, ME). Animals were immunized 
subcutaneously twice, two weeks apart (Figure 2.6) with 100 µL of vaccine using a 28g 
insulin syringe (Becton Dickinson Cat# 3294161). Vaccine groups consisted of PBS 
(vehicle control), ovalbumin (OVA, 10 µg), OVA + PorB (10 µg), OVA+ CpG (10 µg), 
and OVA+ aluminum salts (alum, 200 µg) for the first injection. The second injection 
replaced OVA with OVA-A594. Therefore, the second injection groups were PBS 
Vaccines: 
• OVA
• OVA + PorB
End points: 
•IF
•OVA – 350 (original injection)
• OVA – 594 (second injection)
D1 D14
Vaccinate Vaccinate
+OVA594
D15
Sacrifice
Fig re 2.8: Immunization Schedul  f r Secondary Exposure to Antigen 
and Adjuvants 
Figure 2.6: Experimental Design for Antigen Deposition After Booster Injection. 
Animals were immunized subcutaneously twice, two weeks apart with 100 µL of subcutaneously. Vaccine 
groups consisted of PBS (vehicle control), ovalbumin (OVA, 10 µg), or OVA + PorB (10 µg) for the first 
injection. The second injection replaced OVA with OVA-A594. Therefore, the second injection groups 
were PBS (vehicle control), OVA-A594 (10 µg) or OVA-A594 + PorB. Draining lymph nodes were 
isolated and analyzed by immunohistochemistry one day post the booster injection. 
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(vehicle control), OVA-A594 (10 µg), OVA-A594 + PorB, OVA-A594 + CpG (10 µg), 
and OVA-A594 + Alum. Draining iliac lymph nodes were isolated and analyzed by 
immunohistochemistry on a confocal microscope.  
Immunohistochemistry for Antigen Deposition on Follicular Dendritic Cells after Second 
Injection  
Draining iliac lymph nodes were prepared for IHC as previously described above. 
The following antibodies were used: primary for ovalbumin (OVA, ThermoFisher 
Scientific Cat#PA1-196, dilution 1:100), anti-rabbit Alexa-350 (ThermoFisher Scientific, 
Cat#A10039, dilution 1:200), primary (FDC-M1, BD Biosciences, Cat#551320, dilution 
1:100), secondary anti-rat 488 (Biolegend, Cat#405418, dilution 1:200). Slides were 
mounted with DAPI and allowed to air dry overnight. Images were taken on the Lecia 
Sp5 at 63x oil immersion objective. The images were arranged and analyzed using 
ImageJ (NIH).   
Quantification of OVA Deposited on Follicular Dendritic Cells after Booster Injection 
 To quantify if OVA had been deposited during the first injection or second, 
ImageJ analysis was used with Pearson Correlation Coefficient. Since OVA in the first 
subcutaneous injection was not labeled, the anti-OVA antibody, with Alexa-350 
secondary, would identify this OVA. The second injections included OVA-A594 and, 
therefore, would be able to be identified and differentiated from the OVA in the initial 
injections. Similarly to the colocalization of OVA with FDC listed above, JaCoP was 
used to determine Pearson correlation coefficients for Alexa350 with FDC and Alexa594 
with FDC. To ensure the Alexa350 was not recognizing an epitope of Alexa594, 
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Mander’s correlation coefficients were determined between Alexa350 and Alex594.   
Methods for Chapter Four 
Animals 
 Four to eight weeks old C57Bl/6J (referred to as ‘wild type’, stock #000664) mice 
were obtained from Jackson laboratories (Bar Harbor, ME). All mice were maintained 
within the Laboratory Animals Science Center (LASC) at Boston University School of 
Medicine under Dr. Lee Wetzler’s animal protocol 14155. The Boston University 
Institutional Animal Care and Use Committee (IACUC) approved all research conducted 
using animal models.   
CD169 knockout mice were a gift. Polymerase chain reaction (PCR) was 
performed on these animals to ensure the genotype was correct.  
Genotyping for CD169 Global Knockout  
CD169 knockout animals were ear punched after weaning for genotyping. 
RedExtract-N-Amp Tissue PCR Kit (Sigma, Cat#E7526) was used according to 
manufactures protocol. PRC reaction was prepared using RedExtract-N-Amp Tissue PCR 
Kit (Sigma, Cat#R4775) according to manufacturer’s protocol.  
CD169: 
Primers: 
CAC CAC GGT CAC TGT GAC AA – Forward 
GGC CAT ATG TAG GGT CGT CT – Reverse 
Both primers were used at a final concentration of 1µM. 
PCR Program:  
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92°C for 2:00 
92°C for 0:30 
57°C for 0:30 
72°C for 1:30 
Go to step #2 for 35 times 
72°C for 5:00 
4°C forever 
Expected results:  
Wildtype: 486 bp 
Transgene: 1700bp 
Specificity of Low-Dose Clodronate for Subcapsular Macrophages  
Clodronate (Liposoma Research, SKU:C-005) treated animals received 
intravenous (IV) tail vein injections with different doses of clodronate – either high dose 
(40 mg/kg) or low dose (6.5 mg/kg). Low dose clodronate has been previously published 
to deplete the subcapsular subtypes of macrophages within the lymph node (Tracy L. 
McGaha, Chen, Ravishankar, Rooijen, & Karlsson, 2011). 24 hours post IV injection, 
flow cytometry and immunohistochemistry (IHC) was used to determined depletion of 
CD169+ macrophages. Briefly, inguinal lymph nodes were isolated and placed in cold 
PBS for flow cytometry analysis. Iliac lymph nodes were isolated and placed in molds 
(ThermoFisher) with optimal cutting temperature (OCT) medium (Richard Allan 
Scientific). These samples were frozen on dry ice for immunohistochemistry (IHC).  
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Vaccine Regime 
 Wild type and CD169 knockout mice between the ages of four to eight weeks 
were immunized subcutaneously with 100 µL vaccine using a 28g insulin syringe 
(Becton Dickinson Cat# 3294161) (Figure 2.7A). Vaccine groups consisted of PBS 
(vehicle control), ovalbumin (OVA, 10 µg), OVA + PorB (10 µg), OVA+ CpG (10 µg, 
Invivogen, Cat# ODN1826), and OVA+ aluminum salts (alum, 200 µg Sigma, Cat# 
A8222). Clodronate treated groups received an IV tail vein injection one day prior to 
subcutaneous vaccinations. For immunoglobin (IgG) studies, mice were vaccinated three 
times, two weeks apart as shown in Figure 2.7A. Two weeks after the final injection, the 
animals were sacrificed and the blood collected for antigen (ovalbumin, OVA) specific 
immunoglobin ELISAs (n=6-12). The concentrations and volumes for vaccines were 
from previously determined publications (Platt et al., 2013).  
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For antigen deposition onto follicular dendritic cells, mice were vaccinated 
subcutaneously and euthanized 24 hours post injection (Figure 2.8). Vaccination groups 
consisted of ovalbumin (OVA) fluorescently labeled with Alexa 594 (OVA-A594, Life 
technologies) alone, OVA-A594 + PorB, OVA-A594 + CpG, or OVA-A594 + Alum. 
Draining lymph nodes were isolated for IHC and flow cytometry analysis 
D0 D1 D13 D14 D27 D28 D42
Clodronate Clodronate Clodronate
Vaccinate
Sacrifice 
Vaccines: 
• PBS
• OVA
• OVA + PorB
• OVA + CpG
• OVA + Alum
Vaccinate Vaccinate
End points: 
• IgG ELISA
• IgG subtypes
D0 D1 D13 D14 D27 D28 D42
Bleed
Vaccinate
Sacrifice 
Vaccinate Vaccinate
Bleed Bleed
Clodronate Experimental Design
B6 Control and CD169 KO Experimental Design
a. 
Figure 2.7: Experimental Design for Antibody ProductionA.		
B.		
Figure 2.7: Experimental Design for Antibody Production. 
(A) Low dose clodronate and (B) CD169 knockout and wildtype immunization schedule. This schedule 
was modified from a previously published immunization schedule from our lab. Mice were divided into 2 
groups – one group receiving low dose clodronate treatment one day prior to immunization and the other 
group receiving encapasomes control. These groups were further divided into PBS, OVA, OVA+ PorB, 
OVA+ CpG, or OVA+Alum. Mice received subcutaneous immunizations 3 times, with 2 weeks in 
between immunizations. Two weeks after the final immunization, mice were sacrificed and sera collected. 
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Flow Cytometry of CD169+ Macrophages and Follicular Dendritic Cells 
Draining lymph nodes were isolated for flow cytometry and placed in cold PBS 
immediately after isolation. Single cell suspensions were prepared as follows unless 
indicated otherwise. Tissues were pushed through a 70 µm cell strainer. Samples were 
then incubated for 3 minutes in ACK (150 mM NaH4CL, 50mM KHCO3) buffer to lysis 
red blood cells. The samples were then washed in PBS and re-filtered through a 70 µm 
cell strainer. At this point, samples were counted and stained for flow cytometry. Cells 
were incubated with a live/dead stain (Biolegend, Cat#423105) for 30 minutes, in the 
dark at 4 °C. Cells were then washed with 5x FACSBuffer (PBS, 0.5%BSA, and 2% 
EDTA) and spun down. Cells were then incubated with CD16/CD32 Fc block 
(eBioscience, 48-0032-82) for 10 minutes in the dark at room temperature. Cells were 
then plated in a 96 V-well bottom plate (Corning, CLS3896-48EA) and stained. All 
dilutions were 1:200 unless noted. For subcapsular sinus macrophages analysis, 
Vaccines: 
• OVA
• OVA-A594
• OVA-A594 + PorB
• OVA-A594 + CpG
• OVA-A594 + Alum
End points: 
•IF
• FDCs 
• OVA-A594
D1 D2
Vaccinate
OVA594 +/-
Adjuvants
Sacrifice
Supplemental Figure 4: Experimental Design Set for FDC Frequency and 
Antigen Deposition on FDCs 
Figure 2.8: Experimental Design for Antigen Deposition on to Follicular Dendritic Cells. 
Mice were divided into 5 groups: OVA, OVA-A594, OVA-A594 + PorB, OVA-A594+ CpG, or OVA-
A594+Alum. Mice received subcutaneous injections above the base of the tail. 24 hours post injection, 
mice were euthanatized and draining lymph nodes isolated for analysis.  
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antibodies included: CD169-FITC (Bio-Rad, 0308), CD11b–PE (Biolegend, 123128), 
CD19-BUV395 (BD Horizon, 563557), F4/80–PerCP5.5 (Biolegend, 123128) CD3–
eFlour (Invitrogen, 48-0032-82), CD11c–APC (BD Pharmigen, 550261). Gating strategy 
is shown in Figure 2.9A. A fluorescence minus one (FMO) stain was used where all the 
antibodies in the panel are present with the exception of CD169 as shown in Figure 2.9B.  
For FDCs, single cell suspensions were prepared as previously reported (Usui et 
al., 2012) and is briefly described. Draining lymph nodes were placed in cold PBS and 
manually minced on a petri dish with a scalpel. The samples were transferred to a 24-well 
plate (FisherScientific, Cat #08-772-1H), incubated with DMEM containing 2% FBS 
(ThermoFisher, Cat#26140079), 33.3 mg/ml collagenase type IV (ThermoFisher, 
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Figure 2.9A: Gating Strategy for CD169+ Macrophages
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Figure 2.9B: Gating Strategy for CD169+ Macrophages with FMO
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Figure 2.9: Gating Strategy for CD169+ Subcapsular Macrophages with FMO. 
A) Gating strategy for CD169+ SCS macrophages within draining lymph node. (B) FMO for CD169 from 
panel shown in (A). 
		
43 
Cat#17104019), and 2500 U/mL DNase I (ThermoFisher, Cat#18047019). Samples were 
incubated for 1 h at 37°C. After which, the samples were strained through 70 µm filter, 
although not pushed through to ensure the integrity of the FDCs remained intact. Cells 
were then stained as described above. All antibody dilutions were 1:200 unless otherwise 
noted. CD21/CD35 – BV421, CD45 – APC, CD19 – BUV395 (1:400), ICAM-1 – FITC. 
Gating strategy is shown in Figure 2.5A. A FMO was stained for all colors within the 
panel excluding CD21/CD35 shown in Figure 2.5B. All samples were analyzed on an 
LSRII, a machine available within the Boston University flow core, on a low flow 
setting. 
Immunohistochemistry for Subcapsular Macrophages and Antigen Deposition onto 
Follicular Dendritic Cells 
To confirm low dose clodronate would deplete CD169+ specifically, lymph nodes 
were isolated 24 hours after IV injections of either vehicle controls, low dose clodronate 
treatment (6.5 mg/kg), or high dose clodronate treatment (40 mg/kg). Draining lymph 
nodes were then put into molds containing optimal cutting temperature (OCT) medium 
(Richard Allan Scientific, Kalamazoo, MI, USA) and frozen on dry ice. Tissues were cut 
on a microm HM 550 (Microm International GmBH, Germany). 8 µm sections were 
obtained and placed on Colorfrost Plus slides and stored at -80°C until staining. Sections 
were air dried for 15 minutes at room temperature, then fixed in acetone at −20°C for 10 
minutes and air dried for 10 minutes. Sections were re-hydrated in TBST then blocked 
for 30 minutes at room temperature with TBST with 5% BSA. Sections were rinsed with 
PBS and then stained with antibodies for overnight at 4°C followed by three rinses with 
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PBS. For clodronate specificity studies, the following antibodies and reagents were used: 
FITC hamster anti-mouse CD169 (Biolegend, Cat#142405) and F4/80 (Biolegend, 
Cat#123127). All antibodies were used at 1:200 dilution. For antigen deposition on 
FDCs, draining lymph nodes were isolated 24 hours post subcutaneous injections and 
stained with conjugated (CD11c, Biolegend, Cat#117309) and primary (FDC-M1, BD 
Biosciences, Cat#551320) antibodies overnight at 4°C followed by three rinses with PBS. 
Secondary antibody (anti-rat 488, Biolegend, Cat#405) was added to the slides for 1 h at 
room temperature followed by three washed in PBS. Antibody concentration for the 
primary was 1:100. Conjugated and secondary antibodies were used at 1:200 dilution. 
Stained lymph node sections were mounted in Fluoroshield mounting medium with DAPI 
(Abcam) and dried overnight. A Leica SP5 confocal microscope (Leica AG) was used to 
examine all sections using the Leica LAS AF the 10x and 63x oil immersion objectives. 
The images were arranged and analyzed using ImageJ (NIH).  
Enzyme-Linked Immunosorbent Assay (ELISA) for Measurement of OVA Specific 
Antibodies 
Sera was collected at the time of euthanasia via heart sticks from all animals. 96 
well immulon 2 HB (ThermonFisher 3455) were coated with 5 µg/mL of OVA in 
carbonate buffer and incubated overnight at 4°C. Sera was diluted in tris-buffered saline 
and tween (TBST, 0.05% Tween) starting at 1:50. The dilutions were then added to the 
coated plates. A serial dilution for each sample was done horizontally across the plate. 
The plates were then incubated overnight in 4°C. The plates were then washed with 200 
µL/well with 0.05% TBST three times. Alkaline phosphatase-conjugated anti-mouse total 
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IgG or IgG1or IgG2c subclasses (Sigma Aldrich, St. Louis, MO) was added to each well 
and incubated at room temperature for 1 hour. Plates were then washed again and 
developed with one-step p-nitrophenyl phosphate (Pierce, Rockford, IL). The optical 
density was measure on BioTek Synergy HT and analyzed with the Gen5 software. For 
total IgG, colorimetric values were converted to nanograms/mL from a standard curve 
created in ImageJ software as previously described(Mackinnon et al., 1999). End point 
titers were determined for IgG subclasses.  
Statistics  
Statistics were calculated in GraphPad Prism (version 8.0). Differences in OVA-
specific IgG and IgG subtypes in were calculated by T tests between wild type control 
animals and clodronate treated animal or CD169 knockout animals. ANOVA with 
Sidak’s multiple comparisons test was used for all other analysis. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001  
Methods for Appendix 
Study Design to Investigate if PorB Increases CD169+ Subcapsular Macrophages  
A kinetic study using OVA-A594 (10 µg per mouse) given alone or with PorB 
(10 µg per mouse), was performed to determine if PorB increased CD169+ subcapsular 
macrophages. All mice were injected subcutaneously near the base of the tail. Draining 
lymph nodes were isolated after euthanasia 24, 48 or 72 h after immunization (Harrell et 
al., 2008). The lymph nodes were prepared for single cell suspensions to allow for 
analyze via flow cytometry 
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Flow Cytometry for CD169 
 Flow for CD169+ from single cell suspensions was done as described above.  
Bone Marrow Derive Dendritic Cells (BMDC) differentiation  
Bone marrow derived dendritic cells were generated as previously reported (Reiser et al., 
2017). Briefly, C57Bl/6J mice were euthanized and their femurs were cleaned from 
muscle and fur. The femurs were then flushed with PBS using a 25 G needle. To ensure 
erythrocytes were lysed, all samples were incubated with ACK (150 mM NaH4CL, 
50mM KHCO3) buffer for 3 minutes at room temperature. Cells were then strained 
through a 70 µm nylon mesh (ThermoFisher Scientific, USA). Cells were then counted 
and plated at 3x105 cells/plate concentration. RPMI-1640 with 10% FCS (Gibco), 100 
U/mL Penicillin-Streptomycin (Sigma-Aldrich), and 20 ng/mL GM-CSF (Sigma-Aldrich, 
#SRP3201) was used for the media for BMDCs.  On day four, 5 mL of fresh media was 
added to the plate. On day six, cells were spun down, counted, and plated for 
stimulations. 
Study Design for Cytokine Expression of BMDCs Stimulated with Multiple TLR-ligand 
Based Adjuvants 
 BMDCs were seeded into 96-well plates at 10x5 cells/well and allowed to rest for 
2 hours prior to stimulation. One row was left untreated as a control. The remaining cells 
were stimulated with either OVA (5µg) or OVA plus adjuvants. The adjuvants used 
individually were: PorB (10µg/mL), Poly(I:C) (10µg/mL), or Pam3CSK4 (0.1µg/mL). 
The combinations tested were OVA+ PorB + Poly(I:C) and OVA+PorB+Pam3. 6 hours 
after stimulation, supernatants were collected in order to determine cytokine expression 
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via ELISA.  
Enzyme-Linked Immunosorbent Assay (ELISA) for IL-6, TNF α, and IFN β 
  Supernatants from stimulated BMDCs were removed from the cells and analyzed 
for cytokine levels by ELISA. Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF- 
α) per manufactures instructions. The IL-6 ELISA kits were purchased from eBioscience 
(#88-7324-88) and the TNF- α kit was purchased from R&D Systems (#DY406). 
Interferon beta (IFNβ) was analyzed as previously described (Liehl et al., 2014). Briefly, 
2HB plates were coated with monoclonal IFNβ antibody (0.1 µg/ml) (Santa Cruz, #sc-
57201) in carbonate buffer. Samples and known IFNβ standard concentrations (PBL 
assay science, #12405-1) were incubated over night after blocking wells for 2 h with 
PBS/BSA 1%. IFNβ was detected using an anti-mouse IFNβ, polyclonal rabbit IgG 
(1:2000), (PBL assay science, #32400-1) for 2 h and donkey anti-rabbit IgG antibody, 
HRP conjugated (1:2000) (EMD Millipore, #AP182P) for 1 h. BD HRP substrate (BD, 
#555214) was used to develop ELISA at 450 nm. OD values for TNFα, IL-6, and IFNβ 
were determined at 450 nm and calculated based on standard curves generated by known 
amounts of recombinant TNFα, IL-6, and IFNβ using GraphPad Prism (version 8.0). 	 	
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CHAPTER THREE:  
Toll-like Receptor Ligand Based Adjuvant, PorB, Increases Antigen Deposition on 
Follicular Dendritic Cells while Enhancing Follicular Dendritic Cell Networks 
Introduction 
Vaccines are one of the most significant advancements in modern medicine. 
Utilizing vaccines, smallpox has been eradicated and measles infection rate dropped by 
80% from 2000-2017("Immunization," 2019). Yet there are still infectious diseases 
where the empirical methods have failed to produce a successful vaccine. In order to 
produce more effective vaccines, researchers have developed subunit vaccines, which 
consist of two main components – antigen and adjuvant (Rueckert & Guzmán, 2012). 
The antigen is a small molecule against which can induce a protective response but only 
with the addition of the adjuvant, which provides immunostimulation to induce this 
response (Di Pasquale et al., 2015; Moyer et al., 2016; Steven G. Reed et al., 2013). 
Antigen alone has not been able to sufficiently provide protection therefore the addition 
of adjuvants has become critical. Adjuvants were described as Charles Janeway’s 
immunologist “dirty little secret” which defined pathogen associated molecular patterns 
(PAMPs) from microbial origins, which activated innate immune cells (Janeway, 1989). 
PAMPS are recognized as “non-self” molecules by pattern recognition receptors (PRRs) 
on innate immune cells (Janeway & Medzhitov, 2002). There are multiple families of 
PRRs including membrane-bound receptors and cytoplasmic. One subclass of PRRs is 
Toll-like receptors (TLRs). TLRs can be extracellularly located or within endosomes 
(Averett et al., 2007; Iwasaki & Medzhitov, 2004). TLR engagement which activates 
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downstream intracellular signaling cascades and induce cytokine production, have been 
very well characterized (Chaturvedi & Pierce, 2009; Kawai & Akira, 2010). These 
characteristics account for the fact that many TLR-ligands are effective vaccine 
adjuvants(Iwasaki & Medzhitov, 2004). Investigators can select certain TLR-ligand 
based adjuvants to examine specific cellular pathways within the immune system and 
draw conclusions based on protection and adaptive immune responses.  
Our laboratory has investigated the adjuvant properties of the major outer 
membrane protein from Neisseria meningitidis, PorB. We have shown that PorB, a 
TLR2/1 ligand, is able to significantly increase co-stimulatory ligands expression and 
cytokine production in antigen presenting cells (APC) (Platt et al., 2013). In addition, 
PorB can increase antigen loaded APC trafficking to the lymph node (Reiser et al., 2017), 
induce germinal center formation (M. M. Mosaheb et al., 2017), and enhance antigen 
specific antibody production, CD4+ T cell activation (M. Mosaheb & Wetzler, 2018), and 
cross presentation allowing for CD8+ T cell activation (Reiser et al., 2017).  We have 
mainly used subcutaneous immunizations for these studies; however, the effect of 
adjuvants of the microenvironment of the draining lymph nodes from these injections has 
not be extensively investigated. In the current studies, utilizing fluorochrome labeled 
antigen, we investigated the fate of intact antigen in the draining lymph nodes 24 hours 
post-immunization in mice and whether adjuvants influence this process. In addition to 
PorB, we also examined the effect of CpG, an intracellular TLR-ligand based adjuvant, 
and a non-TLR adjuvant, aluminum salts (Alum). Both of these adjuvants have been 
shown to increase cytokine expression in innate immune cells (Kumagai, Takeuchi, & 
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Akira, 2008), (Kimura et al., 1994) (Franchi & Núñez, 2008) and increase antigen 
specific antibodies (Gupta, 1998), (Chu et al., 1997). To date, the immune cells that result 
in a protective response after vaccination including adjuvants have not been fully 
described.  
Multiple cellular interactions are needed to induce a protective antibody response. 
One critical initial step is antigen reaching the lymph node, either by trafficking as 
processed antigen in dendritic cells (DCs) or as free intact antigen from the lymphatic 
vessels. DCs are the primary APC during vaccine induced immune responses, taking up 
antigen at the immunization site, processing such antigen while trafficking to the 
secondary lymphoid organs (SLO) (Alvarez, Vollmann, & von Andrian, 2008). The 
antigen containing DCs are needed to stimulate T follicular helper cells (Tfh), which can 
then further enhance antigen specific B cell activation during the germinal center 
response (Förster et al., 2012). Free intact antigen exits lymphatic drainage via 
subcapsular sinus (SCS) macrophages and are eventually deposited on follicular dendritic 
cells FDCs, likely by non-cognate B cell, though this is unclear (Tri Giang Phan et al., 
2009).  FDCs are stromal cells within the lymph nodes and spleen which are located in 
the B cell light zone of the germinal center and are vital for induction of B cell somatic 
hypermutation and antibody (Ab) affinity maturation. They could also be involved with B 
cell differentiation into memory B cells or long-lived plasma cells (Allen & Cyster, 
2008). FDCs recycle antigen and antigen-antibody complex (known as immune 
complexes, IC) to the cell surface via actin-requiring processes (Nossal, Ada, Austin, & 
Pye, 1965) without proteolytically processing the antigen. Once the B cell receptor is 
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engaged with the native antigen on the FDC, cytokines and chemokines are secreted for 
induction of B cell survival, allowing for 1) exiting the germinal center completely if 
high affinity interactions with intact antigen occur, 2) re-entering the B cell dark zone of 
the germinal center if moderate affinity to intact antigen occurs, for further activation by 
antigen specific Tfhs along with induction of somatic hypermutation or 3) apoptosis if 
they have low affinity for their antigen (Kranich & Krautler, 2016). To date, very few 
studies have investigated how adjuvants influence this process, especially in regards to 
antigen association with FDCs (Rocco Cantisani et al., 2015; R. Cantisani & Piccioli, 
2015). Cantisani et al. showed increased FDCs in the draining lymph node with the 
inclusion of oil-in-water adjuvant.  
The studies presented here were designed to determine the effect of adjuvants on 
the initial steps involved in induction of B cell activation in the germinal center which 
would subsequently lead to induction of high affinity antibodies. We examined the effect 
of adjuvants on the level of intact antigen present in the lymph node, deposition of this 
antigen on FDCs and the overall quality of the FDC network and present data from these 
studies below. These studies highlight in what manner adjuvants, especially PorB, may 
influence vaccine antigen interaction with cells in the germinal center and influence 
antibody production essential for vaccine efficacy. We have published multiple papers 
proving PorB’s adjuvant characteristic which resulted in higher antigen specific antibody 
levels as well as more diverse antigen specific subtypes than other adjuvants tested (M. 
Mosaheb & Wetzler, 2018; M. M. Mosaheb et al., 2017) which substantiates our 
approach taken in these studies. 
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 Results 
Ovalbumin (OVA) Fluorescently Labeled with Alexa-594 (OVA-A594) is Taken up 
by Antigen Presenting Cells (APCs) without Increasing Co-Stimulatory Factors  
The initial study was to determine if OVA-A594 would be taken up by antigen 
presenting cells (APCs) without stimulating the cells. To test this, we incubated OVA-
A594 with bone marrow derived macrophages (BMDM). BMDMs were incubated with 
either PBS, OVA-A594, or OVA-A594 + PorB for 0.2 hours (hr), 1hr, 2hr, and 3hrs. 
After 3 hours, BMDMs were washed thoroughly to ensure the presence of 594 was 
within the BMDMs. The gating strategy for these cells is shown in Figure 3.1A where 
events were gated on live cells, CD11c+CD11b+594+. Costimulatory factor, CD86, was 
also used in the flow panel to guarantee OVA-A594 was not stimulating the BMDMs. As 
shown in Figure 3.1B, PBS showed no significant events in the 594+ gate. OVA-A594 
stimulated cells were positive for OVA-A594 as shown by the brighter 594 stain. The 
addition of PorB to OVA-A594 increased the CD11c+CD11b+594+ an additional 20% 
from OVA-A594. These results are summarized in Figure 3.1C Lastly, Figure 3.1D 
shows that no treatments increased levels of CD86.   
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Figure 3.1: Bone Marrow Derive Macrophages Increase Antigen (OVA-A594) Uptake with 
PorB. 
A) Gating strategy for bone marrow derived macrophages (BMDM). (B) Final gate of gating strategy 
shown in (A) of OVA-A594 within samples; PBS, OVA-A594 alone, or OVA-A594 + PorB. (C) Mean 
Fluorescence Intensity (MFI) of OVA in BMDMs after 0.2h, 1h, 2h, and 3h. (D) MFI of CD86 in BMDMs 
after 0.2h, 1h, 2h, and 3h. 
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PorB Increases Antigen Deposition on Follicular Dendritic Cells in Kinetic Study 
Follicular dendritic cells (FDCs) have not be thoroughly investigated by 
stimulation of adjuvants. We hypothesized that adjuvants would increase FDCs as well as 
increase antigen deposition onto FDCs. To test these hypotheses, a time course to 
measure labelled ovalbumin (OVA-A594) which colocalized with follicular dendritic 
cells (FDC-M1) within the iliac lymph nodes after subcutaneous injection was preformed. 
The study design is shown in Figure 2.1 and only contained OVA-A594 and OVA-A594 
+ PorB. The ImageJ plugin, JaCoP, analysis revealed that injections including PorB had 
significant co-localization when compared to OVA-A594 alone 24 hours post injection 
(Figure 3.2). 
Figure 3.2: FDC-M1 and OVA-A594 Colocalization Kinetic Study
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Figure 3.2: Pearson Correlation Coefficient of OVA-A594 and Follicular Dendritic Cells. 
Pearson correlation coefficient between OVA and FDC in iliac lymph nodes. Mice were divided into 3 
groups – 72 hours, 48 hours, or 24 hours for post injection euthanasia. These groups were further divided 
into OVA-A594 or OVA-A594 + PorB. All injections were subcutaneous. *p<0.05, **p<0.01  
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Mean Fluorescence Intensity of OVA Increased with PorB Injections 
At first, we needed to confirm that adjuvants could influence the presence of intact 
antigen in the secondary lymphoid organs (SLO) 24 hours post subcutaneous injection. 
This outcome is important, because antigen presence within the lymph node is a primary 
factor contributing to the establishment of an adaptive immune response. The groups we 
analyzed consisted of mice immunized with OVA labeled with Alexa594 (OVA-A594), 
OVA-A594 + PorB, OVA-A594 + CpG, and OVA-A594 + Alum. To determine whether 
adjuvants influenced antigen distribution within the lymph nodes of the animals in this 
study, the average mean fluorescence intensity (MFI) of OVA in the draining lymph 
nodes was calculated from immunohistochemistry (IHC) images (Figure 3.3). 
Interestingly, only PorB appeared to increase the amount of labeled OVA within the 
lymph nodes. This increase was significant over other adjuvants used in these studies. 
Figure 3.3: OVA Distribution in Iliac Lymph Nodes
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Figure 3.3: PorB Increases Antigen Presences in Draining Lymph Node. 
PorB increases antigen presence in draining lymph node. Mean fluorescent intensity (MFI) of antigen 
(OVA) in draining lymph nodes 24 hours post vaccination of either OVA-A594, OVA-A594+PorB, OVA-
A594+CpG, or OVA-A594+Alum. MFI of OVA was quantified by the ImageJ measurement tool after the 
subtraction of the background. Representative of three experiments. n= 5-7 *p<0.05, **p<0.01, 
***p<0.001 
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Follicular Dendritic Cell Networks are Increased by TLR-Ligand Based Adjuvants 
To determine if the adjuvants directly affected the quality of the FDC networks, 
we performed immunohistochemistry immunofluorescent staining on draining lymph 
nodes from immunized mice using fluorochrome labeled FDC-M1, which is the common 
marker for FDCs. This study included mice immunized with four different preparation as 
previously described: OVA-A594 (fluorescently labeled with Alexa 594), OVA-A594 + 
PorB, OVA-A594 + CpG, and OVA-A594 + Alum. Samples were analyzed by ImageJ to 
calculate the MFI values for FDC-M1 (Figure 3.4B). Figure 3.4A displays representative 
images of FDC-M1 labeling in draining lymph nodes 24 hours post immunization as a 
heat map, where white indicates the highest signal to pixel ratio and blue shows the 
lowest signal to pixel ratio. Lymph node FDC-M1 labeling was low in mice immunized 
with OVA alone or Alum + OVA. However it was greatly increased when TLR-ligand 
based adjuvants (PorB and CpG) were used as shown in both Figure 3.4A and B. 
To confirm these results, flow cytometry was utilized to quantify FDC numbers in the 
draining lymph nodes. The gating strategy is shown in Figure 2.5. FDCs were defined as 
CD19-CD45-Cr1/Cr2+ICAM-1+. As shown in Figure 3.4C, the flow cytometry data 
matched the IHC data. Animals vaccinated with PorB or CpG with OVA demonstrated a 
significant increase in FDC numbers in the draining lymph nodes as compared to the use 
of Alum + OVA or OVA alone. 
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Figure 3.4C. FDC+ Events of Live 
Cells in Inguinal Lymph Nodes
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Figure 3.4: Evaluation of the Effect of Adjuvants on FDC Networks. 
A) Representative images for FDC expression in draining lymph nodes 24 hours post subcutaneous 
injections of either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. FDC 
expression is shown as a heat map where white indicates the highest signal to pixel ratio and blue sows the 
lowest signal to pixel ratio. Scale bar is 100 µM. One of 3 representative experiments is shown. (B) Mean 
fluorescence intensity (MFI) quantification from ImageJ of FDC networks in draining lymph nodes 24 
hours post injection of either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. 
Multiple FDC networks were measured within individual lymph nodes. n=9/group. *p<0.05, ***p<0.001 
(C) Frequency of FDC in draining lymph nodes 24 hours post subcutaneous injections with OVA-A594 
+/- adjuvants. Gating strategy is shown in supplemental figure 4. n=9 per group *p<0.05, **p<0.01 
B.		A.	 C.		A.	
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Antigen Deposition on Follicular Dendritic Cells is Increased with PorB and Alum 
As antigen deposition on FDCs is important and likely more biologically relevant 
than actual FDC numbers, the ability of adjuvants to influence antigen deposition onto 
FDCs was examined. Draining lymph nodes from immunized mice described above were 
examined by immunofluorescence microscopy to determine colocalization of labeled 
OVA with FDCs. As displayed in Figure 3.5A, non-adjuvanted OVA-A594 was 
minimally present in the lymph node 24 hours post-immunization. When adjuvants were 
included, OVA-A594 was detectable within the lymph node, regardless of the adjuvant 
administered. Lymph nodes from mice given OVA-A594 + PorB had the most OVA 
present. Lymph nodes from mice given OVA-A594 + PorB or OVA-A594 + Alum had 
multiple areas of colocalization of OVA with FDC (shown by yellow arrows). There 
appeared to be less colocalization when CpG was used. JaCoP was used to quantify 
colocalization between OVA and FDC signal in each tissue section, as previously 
performed in our lab. The Pearson Correlation coefficient from JaCoP confirmed 
significant increases of colocalization in the lymph nodes from mice given OVA-A594 + 
PorB and OVA-A594 + Alum as compared to lymph nodes from mice given OVA-A594 
alone (Figure 3.5B).  
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Figure 3.5: Adjuvant Effect Colocalization of Antigen onto FDCs. 
(A) Representative IHC images from draining lymph nodes from B6 control mice 24 hour post 
subcutaneous injections. FDCs are shown in green. OVA-594, used as a non-immunogenic antigen, is 
shown in red. Areas of colocalization are shown with yellow arrows. Scale bar represents 20µM. One out 
of 3 representative experiments is shown. Images were taken at 63x objective using a Leica SP5 
microscope. (B) Quantification of Colocalization of fluorescently labeled OVA-A594 with FDCs within 
draining lymph nodes 24 hours post subcutaneous injections. Colocalization was assessed using Pearson 
Correlation coefficients calculated with JaCoP plugin in ImageJ after background subtraction. n=9-12 
**p<0.01, ***p<0.001 
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FDC Colocalization is Independent of Antigen Loaded Dendritic Cells  
To ensure the OVA correlation with FDCs was not due to concomitant presence 
antigen loaded DCs, we examined draining lymph nodes by IHC for DCs (as labeled by 
anti-CD11c fluorochrome labeled Ab) along with the FDCs. Figure 3.6A demonstrates 
that a majority of the OVA colocalized with either DCs or FDCs in all treatment groups. 
The white arrows emphasize areas of colocalization between DC and OVA, whereas the 
yellow arrow illustrates FDC colocalization with OVA. JaCoP was used to determine 
whether OVA colocalization with FDC vs DC were uniquely and separate. As shown in 
Figure 3.6B, the Pearson Correlation coefficient was not significant for any of the 
adjuvants tested for a direct association between DC and FDC. These data emphasize that 
the OVA deposition on FDCs is increased with adjuvants when compared to OVA alone 
and, in general, is independent of CD11c+ DC trafficking OVA within the lymph node.  
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Figure 3.6: FDC Antigen Deposition is Independent of Antigen Loaded DCs. 
FDC antigen deposition is independent of antigen loaded DCs. Representative IHC images of draining 
lymph nodes from mice 24 hour post subcutaneous injections are shown in (A) where FDC is shown in 
green, OVA-594, used as a non-immunogenic antigen, is shown in red and dendritic cells (DCs, CD11c) 
are shown in cyan. Areas of colocalization between DC and OVA are shown with white arrows. Areas of 
colocalization between FDC and OVA are shown with yellow arrows. Images were taken at 63x objective 
using a Leica SP5 microscope. One out of 2 representative experiments is shown. (B) Pearson’s 
correlation coefficient between FDC and DC (CD11c) in draining lymph nodes 24 hours post 
subcutaneous injections. Colocalization was assessed using Pearson Correlation coefficients calculated 
with JaCoP plugin in ImageJ after subtracting the background and using an unsharp mask filter. 
n=7/group 
A. 
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Dendritic Cells Numbers in Draining Lymph Node were Increased with the Use of 
Adjuvants 
 Dendritic cells (DC) are a critical APC for the adaptive immune responses. To 
determine if adjuvants influence the number of DCs present in within draining lymph 
nodes after immunization, single cell suspensions of these lymph nodes were obtained 24 
hours post injection with OVA-A594, OVA-A594 + PorB, OVA-A594 + CpG, or OVA-
A594 + Alum. We have previously examined this parameter for PorB (Reiser et al., 
2017) but have never compared this to other adjuvants. The gating strategy is shown in 
Figure 2.4A. Our analysis showed a significant increase in cell count with PorB 
adjuvanted vaccines as well as a significant increase in DCs within the draining lymph 
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Figure 3.7: PorB Significantly Increases Cell Counts, DCs, and Antigen Loaded DCs. 
(A) Single cell suspensions were used to calculate cell counts within the draining lymph node 24 hours 
post injection of either OVA-A594, OVA-A594 + PorB, OVA-A594 + CpG, or OVA-A594 + Alum. (B) 
DCs from draining lymph nodes of animals 24 hours post injection from either OVA-A594, OVA-
A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. Gating strategy is shown in supplemental figure 3a. 
Statistics were calculated by ordinary one-way ANOVA with Sidak’s multiple comparisons test.  *p<0.05, 
**p<0.01 (C) Antigen loaded DCs from draining lymph nodes of animals 24 hours post injection from 
either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. Gating strategy is shown 
in supplemental figure 3b and c. Statistics were calculated by ordinary one-way ANOVA with Sidak’s 
multiple comparisons test. n= 3, data represent one of 3 experiments. *p<0.05, **p<0.01 
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node (Figure 3.7 A and B). Interestingly, and supporting our previous work, PorB 
vaccinations showed a significant increase in antigen loaded DCs 24 hours post 
subcutaneous injections (Figure 3.7C).  
PorB Significantly Increases OVA Association with FDCs and DCs as Compared to 
CpG or Alum  
Mander’s correlation coefficients (JaCop within ImageJ) were used to determine 
the percentage of OVA that was associated with either DCs, FDCs, or neither DCs nor 
FDCs. This correlation coefficient allows for spilt channels of correlation to be 
determined (Dunn, Kamocka, & McDonald, 2011).  The percentages of OVA correlated 
with either DCs or FDCs were then multiplied by the MFI of OVA (Figure 3.3) to 
determine the MFI associated with DCs, FDCs, or unassociated. All adjuvants had a 
significant increase in MFI of OVA associated with DCs over the control group, but 
PorB’s increase was significantly greater than the other adjuvants tested (Figure 3.8A) 
which is consistent with our previous data (Reiser et al., 2017). OVA association with 
FDC was also significantly increased when PorB was used as compared to the other 
adjuvants (Figure 3.8B). Lastly, levels of “unassociated OVA”, which we defined as the 
remaining percentage of OVA that was not associated with either DC or FDC 
(Unassociated OVA = 1-[Mander’s coefficient for OVA/DC + Mander’s coefficient for 
OVA/FDC]) was determined. Figure 3.8C shows that OVA-A594 + PorB had the only 
significant decrease in unassociated OVA when compared to other adjuvants and control 
groups. Interestingly, OVA-A594 + CpG had a significant increase in unassociated OVA. 
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These data emphasize that the PorB, as an adjuvant, induced a significant increase in 
antigen associated with both DCs and FDCs when compared to other adjuvants.  
 
PorB Increase Antigen Retention on FDCs and Increases Antigen Deposition After 
Booster Injection 
It has been shown that there is a temporal effect for B cells within the germinal 
center which influences B cells toward a memory B cell population or a long-lived 
plasma cell (Weisel, Zuccarino-Catania, Chikina, & Shlomchik, 2016). It is reasonable to 
believe that antigen presence plays a factor in this pathway. To determine if PorB 
influences time of antigen on FDC, we created a protocol to decipher if OVA was from 
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Figure 3.8: OVA-A594 Distribution Between DC, FDC, and Unassociated OVA within Draining 
Lymph Nodes 24 Hours Post Subcutaneous Injection. 
MFI of OVA associated with DC (A), FDC (B), or unassociated OVA (C) was assessed using the JaCoP 
plugin within ImageJ and determining the Mander’s correlation coefficient after subtracting the 
background. The correlation coefficient is the percentage of DCs or FDCs associated with OVA. This 
percentage was then multiplied by the total MFI of OVA within the lymph node (Figure 1) to determine 
MFI of OVA associated with either DCs or FDCs. These data were assessed in draining lymph nodes 24 
hours post injection of either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. n= 
5-7 *p<0.05, **p<0.01, ***p<0.001.  
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an initial injection or a booster (Figure 3.9A). Analysis via Image J showed PorB 
increased Pearson correlations coefficient of OVA from the first injection (350) with 
FDC compared to OVA control (Figure 3.9B). PorB also increased Pearson correlation 
coefficient of OVA from the second injection (594) and FDC (Figure 3.9C). To ensure 
that the 350 antibody was not recognize an epitope of 594, since 350 was stained after 
594, Mander’s Correlation coefficient was measured. As shown in Figure 3.9D, no 
correlation between 350 and 594 was present in either OVA-alone injections or OVA + 
PorB injections.   
Figure 3.9b-d: Immunohistochemistry of Secondary Exposure to Antigen 
and Adjuvants 
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Figure 3.9A: Immunohistochemistry of Secondary Exposure to Antigen and 
Adjuvants 
OVA-A594
FDC
OVA-A594
FDC 
OVA-350OVA-A594
OVA
OVA + 
PorB
	A.		
OVA-350		 OVA-A594		 OVA350/	OVA-A594		B.	 C.		 D		
Figure 3.9: Antigen Deposition onto FDCs After Booster Injection. 
(A) Representative IHC images from iliac lymph nodes from wildtype control mice 24 hour post boost 
subcutaneous injections. Animals received either OVA alone or OVA+PorB. FDC is shown in green. 
OVA-A594 used as a non-immunogenic antigen, is shown in red from the booster injection. OVA from the 
initial injection is shown in blue. Images were taken at 63x objective using a Leica SP5 microscope. (B) 
Pearson correlation coefficient between OVA-350 (initial injection) and FDC in animals treated with either 
OVA or OVA + PorB. (C) Pearson correlation coefficient between OVA-A594 (booster injection) and 
FDC in animals treated with either OVA or OVA + PorB (D) Mander’s correlation coefficient between 
OVA-A594 and OVA-350. *p<0.05 **p<0.001 
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Discussion 
In order to understand the influence of different adjuvants and multiple pathways 
within the lymph node, we utilized adjuvants that have been associated with enhanced 
immune responses. PorB, a TLR1/2 ligand-based adjuvant, well studied in our lab (Yuen, 
Kuniholm, Lisk, & Wetzler, 2019), was compared along CpG, a TLR9 ligand-based 
adjuvant, and aluminum salts (Alum), a TLR-independent adjuvant. CpG and Alum, 
along with PorB, have been shown to increase antigen-specific antibody responses 
beyond the use of OVA alone, from our group and others (M. M. Mosaheb et al., 2017), 
(Chu et al., 1997). Initially, we demonstrated that PorB was able to significantly increase 
the presence of OVA within the draining lymph nodes 24 hours post subcutaneous 
immunization as compared to CpG or Alum (Figure 3.3). The specificity of the adaptive 
immune response is dependent on the presence of specific antigen within the lymph node 
(Nossal et al., 1965). This is especially in regard to the presence of intact antigen 
deposited on FDCs and processed antigen brought to the draining lymph nodes via DCs.  
FDC are critical for antibody production by providing intact antigen to B cell receptors 
(BCR). Depending on the affinity of the BCR, the B cell will either leave the germinal 
center, return to the dark zone for further somatic hypermutation, or become apoptotic 
based on cytokine expression from the FDCs. Here-in we investigated how adjuvants 
may affect these cells, especially in regards to antigen deposition. We demonstrated that 
TLR-ligand based adjuvants, PorB and CpG, both significantly increased the FDC 
network 24 hours after a subcutaneous immunization by both confocal microscopic and 
flow cytometric analyses (Figure 3.4). FDCs are stromal cells within the lymph node; the 
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increase is likely due to an overall increase in cellularity induced by the adjuvants (Figure 
3.7A, (Reiser et al., 2017). An increase in FDCs would allow for more surface area onto 
which more intact antigen can be deposited during the initiation of the adaptive immune 
response. This could lead to greater interaction with B cells and increased B cell receptor 
specificity by allowing for more B cells to come in contact with the deposited antigen, 
and increasing the kinetics of developing high affinity BCRs and antibodies. 
Interestingly, the use of PorB or Alum as adjuvants with OVA, significantly increased 
antigen deposition on the FDCs, as opposed to no change seen with the use of CpG 
(Figure 3.5).  However, Alum did not increase the number of FDCs overall; PorB was the 
only adjuvant studied that both increased FDC number and intact antigen deposition. 
Other studies have focused on passive immune complex (IC) injections to show 
deposition onto FDCs (Tri Giang Phan et al., 2009). While these passive studies are 
important, antigen still needs to be deposited on the FDCs to allow for BCR interactions 
to allow for B cell somatic hypermutation and enhanced Ab affinity. Our studies uniquely 
focused on primary exposures to antigen and the deposition onto FDCs. Interestingly, 
when we analyzed antigen deposition after a second injection, vaccinations including 
PorB not only showed more antigen present from the initial injection, but also showed an 
increase in antigen deposition on the FDCs from the second injection (Figure 3.9). 
Antigen retention on the FDCs may lead to differentiation between long lived plasma 
cells and memory B cells (Weisel et al., 2016).  
The effect of PorB and the other adjuvants on DC trafficking to the lymph nodes 
and antigen association with DCs was also analyzed. DCs are a critical APCs for the 
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adaptive immune response (Alvarez et al., 2008). Usage of PorB or Alum as an adjuvant 
increased the numbers DCs within the draining lymph nodes (Figure 3.7B). More 
importantly, however, only PorB demonstrated significant increases of antigen loaded 
DCs in these same draining lymph node (Figure 3.7C).  The effect of PorB and other 
adjuvants on DC antigen uptake and trafficking to the lymph nodes is a significant 
mechanism by which they increase antigen specific antibody production through antigen 
presentation to T cells in the secondary lymphoid organs, like Tfh cells, and subsequent 
activation of antigen specific B cells (Alvarez et al., 2008).  
The effect of adjuvants on OVA distribution in the lymphoid follicle and germinal 
center demonstrates, for the first time, the ability of PorB to more efficiently direct intact 
antigen towards cellular pathways directly involved in antibody production as compared 
to other adjuvants tested. Figure 3.8 demonstrates that immunizations including PorB as 
an adjuvant resulted in the majority of labeled OVA MFI in the lymphoid follicle and 
germinal center to be associated with either FDCs or DCs (CD11c). As stated, both of 
these cell types are imperative for effective antibody production due to FDCs interactions 
with B cells and DC interactions with Tfh cells. Interestingly, PorB was also the only 
adjuvant to show a significant decrease in OVA MFI that was not associated with either 
cell type.  This emphasizes that PorB has a more targeted effect toward the adaptive 
immune responses than other adjuvants investigated here.  
Overall, these studies emphasize the role adjuvants have on specific cellular 
mechanisms involved in vaccine induced antibody production. For the first time, 
follicular dendritic cells were demonstrated to be increased in numbers by both 
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extracellular TLR1/2 agonist, PorB, and intracellular TLR9 agonist, CpG. Of these two, 
only PorB also increased antigen deposition onto the FDCs. The timepoint was chosen to 
investigate early innate responses that are involved in the initiation of adaptive immune 
responses. Yuen and Kuniholm have recently highlighted how PorB has major influences 
on the immune system as part of its highly effective adjuvant effect such as increasing 
costimulatory molecules and cytokines expression in bone marrow derived dendritic cells 
as well as antigen-specific IgG antibodies including IgG1, IgG2b, and IgG3 subtypes 
(Yuen et al., 2019). In the studies described above, we have further shown that PorB is 
able to increase draining lymph node antigen levels, FDC numbers, and increase antigen 
deposition on these FDCs. This is certainly related to its significant ability to enhance 
antigen specific antibody production (Platt et al., 2013). Moreover, consistent with 
previous data (Reiser et al., 2017), PorB increases trafficking of antigen loaded DCs to 
the lymph node, separate from the intact antigen deposition on the FDCs. This will allow 
for both increased B cell affinity maturation and increased antigen specific T cell 
induction and activation. Together, these data emphasize the pivotal role of adjuvants in 
immune processes leading to antibody production, along with evidence that PorB has 
characteristics that may make it a superior adjuvant as compared to others.  	  
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CHAPTER FOUR 
The Extracellular Molecule CD169 and Subcapsular Macrophages are Required for 
PorB Adjuvanticity in Antibody Production 
Introduction	
Vaccines represent one of the greatest public health advancements of the last 50 
years, However, there is still a great need for new vaccines for many infectious diseases 
including HIV, malaria, tuberculosis etc. It is imperative that vaccine research continue in 
order to provide protection to these infectious diseases. One way in which vaccine 
research is progressing is the use of subunit vaccines (Moyer et al., 2016). These vaccines 
consist of an antigen to protect against and an adjuvant to stimulate the immune response. 
Adjuvants can be divided up into five main groups – mineral salts, oil emulsion, 
microbial products, saponins, or synthetic products (Steven G. Reed et al., 2013). The 
microbial product group contains a subclass of adjuvants that stimulate through pattern 
recognition receptors (PRR), more specifically Toll-like receptors (TLRs) (Vasou et al., 
2017). TLRs can be either located extracellularly or intracellularly within the endosome 
(Gutjahr et al., 2016; S. G. Reed et al., 2016; van Haren et al., 2016). Depending on 
which TLR is engaged, cellular signal occurs leading to predictable downstream 
stimulation and effects. This predictableness makes TLR-ligand based adjuvants useful 
tools to investigate cellular pathways during an immune response. Our lab has focused on 
these cellular mechanisms of adjuvants, especially PorB, the major outer membrane 
protein from Neisseria meningitidis, which signals through TLR2/1 heterodimers 
(Massari et al., 2006). PorB has been shown to significantly increase adaptive immune 
		
71 
responses, such as antigen-specific antibodies (M. M. Mosaheb et al., 2017; Platt et al., 
2013) and clearance via CD8+ T cells (M. Mosaheb & Wetzler, 2018). PorB has also 
been shown to stimulate antigen presenting cells and enhance adaptive immune responses 
by increasing their expression of co-stimulatory factors, increase their cytokine 
expression, and enhance their antigen cross-presentation (Platt et al., 2013; Reiser et al., 
2017).  
It is well known that innate immune cells have the ability to influence and skew 
the adaptive immune responses in order to protect against pathogens (Coffman et al., 
2010; Fearon & Locksley, 1996; Kawai & Akira, 2010; Zhang et al., 2016). The early 
induction events within the lymph node and spleen, which lead to germinal center 
formation and affinity maturation, remain topics of active research. Complete knowledge 
of such dynamics will lead to a better understanding of infection and prevention by 
utilizing the immune system. Recently our lab demonstrated that conditional knockouts 
of the TLR-signaling molecule MyD88 in macrophages specifically prevented the 
adjuvant effect of PorB in regards to the production of OVA-specific IgG (M. M. 
Mosaheb et al., 2017). Surprisingly, dendritic cells (DC) were not able to rescue the loss 
of MyD88 signaling within the macrophages. These data have led to the work presented 
here which specifically examines the role of subcapsular sinus (SCS) macrophages in 
improved immune responses after vaccination using various adjuvants.   
Multiple studies have indicated SCS macrophages in antigen and immune 
complex retention from the lymph, transportation into the lymph node (Delputte et al., 
2011; Gaya et al., 2015; Junt et al., 2007; T. G. Phan et al., 2007; Szakal et al., 1983), and 
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activation of the adaptive immune response including antigen deposition onto follicular 
dendritic cells (Moalli et al., 2015), antibody production (Desbien et al., 2016) and CD8+ 
T cell activation (Asano et al., 2011; Bernhard et al., 2015; Habbeddine et al., 2017). 
These studies have determined that SCS macrophages exploit their location within the 
lymph node, their unique cellular properties, and the expression of singlec 1 (CD169) 
receptor on the cell surface in order to influence early immune induction events (Ludewig 
& Cervantes-Barragan, 2011; Martinez-Pomares & Gordon, 2007, 2012). The studies 
described here provide critical information about the potential role of these macrophages 
in the effect of vaccine adjuvants, including both TLR-ligand based adjuvants (PorB and 
CpG) and particulate-based adjuvants (Alum) and/or the requirements of CD169 
expression for the effects and enhancement of antigen specific antibody production.  	  
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Results 
In the studies describe below, we used mice with defects in the subcapsular 
macrophages, either lacking CD169 globally (the cells would still be present in this 
model) or removed by treatment with low dose clodronate (only SCS macrophages are 
depleted by apoptosis). CD169 global knockout animals were genotyped to ensure their 
genetic composition was correct. As shown in Figure 4.1, the transgene was present at 
1700 base pair (bp) while the wildtype was at 468 bp.  
In addition, Clodronate liposome treatment has been shown to deplete 
macrophages in the lymph nodes and the spleen by causing apoptosis from increased 
intracellular concentrations of clodronate. At higher doses (40mg/kg) clodronate 
Figure 4.1: CD169 KO PCR gel
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Figure 4.1: PCR to Confirm CD169 Global Knockout. 
Ear punches from newly weaned pups were ran on a PCR gel to determine if the animals were CD169 
global knockouts. Transgene is shown at 1,700 base pairs while the wildtype is at 468 base pairs. 
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liposomes deplete both CD169+ macrophages and F4/80+ conventional macrophages 
whereas lower dosages (6.5mg/kg) result in the preferential depletion of CD169+ 
macrophages in mice (Tracy L. McGaha et al., 2011). To demonstrate this selective 
depletion, fluorescently labeled antibody staining was performed to detect CD169+ and 
F4/80+ expressing cells by both flow cytometry and immunohistochemistry to compare 
CD169+ macrophages after high dose clodronate treatment, low dose clodronate 
treatment, and vehicle control animals. The gating strategy for CD169+ SCS 
macrophages is shown in Figure 2.5. These results are shown in Figure 4.2. High dose 
clodronate showed a significant decrease in both F4/80 and CD169+ macrophages shown 
by both flow cytometry and IHC (Figure 4.C–E) when compared to control animals. As 
shown by McGaha et al., low dose clodronate showed depletion of the CD169+ 
macrophages specifically (Figure 4.2A, B, and E) when compared to both control animals 
and high dose clodronate treated groups.   
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Figure 4.2E: FDC-M1 and OVA-A594 Colocalization Kinetic Study
Figure 4.2: Experiments to Confirm CD169 Specific Macrophage Knockdown with Low Dose 
Clodronate. 
Inguinal lymph nodes were isolated from mice injected 24 hours after an intravenous injection with either 
PBS (vehicle control), low dose clodronate (6.5 mg/kg, LD) or high dose clodronate (40 mg/kg, HD). Flow 
cytometry and immunohistochemistry was used for analysis. (A) The last gate from the gating strategy 
shown in Figure 2.9A, for CD169+ macrophages from PBS, LD, or HD animals. (B) Quantification of 4 
animals for CD169+ frequencies in draining lymph nodes. (C) The F40/80 gate from the gating strategy 
shown in Figure 2.9A, from PBS, LD, or HD animals. (D) Quantification of 4 animals for F4/80+ 
frequencies in draining lymph nodes. (E) Immunohistochemistry in draining lymph nodes from animals 
injected with either PBS, LD, or HD. F4/80 is shown in purple. CD169 is shown in green. The scale bar, 
shown in white, is 100 µM. 	
E. 
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The specificity of low dose clodronate treatment to CD169+ macrophages allowed us to 
investigate the role of these cells in antibody production. The combination of these mouse 
models, CD169 knockout and low dose clodronate treatment, provided us to thoroughly 
investigate the role of the subscapular (SCS) macrophages as well as the CD169 
molecule in antibody production. 
CD169+ Macrophages and the CD169 Molecule are Necessary for TLR Ligand 
Adjuvant-Dependent Antibody Production.  
We hypothesized that use of CD169 KO mice or depletion of CD169+ 
macrophages by low dose clodronate would adversely affect the ability of PorB and 
possibly other adjuvants to induce OVA specific antibodies. OVA specific IgG was 
measured in sera from CD169 KO mice or low dose clodronate treated mice two weeks 
after the third immunization. Figure 4.3A shows OVA-specific total IgG. Alum showed 
the greatest increase in OVA-specific IgG from vehicle control animals. This increase 
was was slightly diminished in low dose clodronate treated mice and CD169 knockout 
mice when compared to wild type mice. Both TLR-ligand based adjuvants, PorB and 
CpG, also showed significant increases in total OVA-specific IgG in wild type animals 
versus vehicle control, as expected (M. M. Mosaheb et al., 2017), however IgG levels 
were greatly decreased in the in low dose clodronate treated mice and CD169 knockout 
mice when compared to similarly treated wild type mice.  
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Figure 4.3A:Total OVA-Specific IgG in Control B6, low dose clodronate 
Treatment and CD169 knockout animals
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Figure 4.3b-d: OVA-Specific IgG Subtypes in Control B6, low dose clodronate 
Treatment and CD169 knockout animals
A.	
B.	 C.	
Figure 4.3: Low Dose Clodronate Treated and CD169 Knockout Animals Significantly Decrease 
Immunization Induced Antigen-Specific IgGs. 
(A) Total ovalbumin (OVA)-IgG (B) OVA-IgG1 and (C) IgG2c concentrations were measure by enzyme-
linked immunosorbent assay (ELISA) following immunizations with PBS, OVA alone, or OVA + PorB, 
OVA + CpG, or OVA + Alum. Wildtype (open bars), wildtype with low dose clodronate treatment 
(stripped bars), or CD169 knockout (checkered bars) mice were immunized three times at 2-week intervals. 
The results shown are from samples collected two weeks after immunizations. n = 7-14 per group. 
Statistics were calculated by ordinary one-way ANOVA with Sidak’s multiple comparisons test.  *p<0.05, 
**p<0.01, ***p<0.001 ****p<0.0001 
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To determine if the loss of CD169+ macrophages or the CD169 molecule itself 
influences IgG responses associated with Th1 or Th2 type responses, OVA-specific IgG 
subtypes were analyzed via ELISAs in the mice described above. These data would 
provide insight on whether subcapsular macrophages and/or CD169 influence Th1 or Th2 
responses. Th2 responses are characterized by IgG1 production while Th1 response are 
characterized by IgG2b and IgG2c production (Germann et al., 1993; Snapper & Paul, 
1987; Stevens et al., 1988). OVA + PorB and OVA + Alum immunized mice had 
significant increases in the OVA-specific IgG1 when compared to vehicle control 
injected mice. However, only OVA + PorB immunized low dose clodronate treated mice 
and CD169 KO mice both had significant decreases in IgG1 as compared to the wild type 
mice (Figure 4.3B). Wild type mice immunized with either TLR adjuvant had a 
significant increase in IgG2c production when compared to vehicle control, which was 
significantly decreased in mice treated with low dose clodronate and CD169 knockout 
animals (Figure 4.3C).  
Induction of Antigen Presence within Lymph Nodes by Adjuvants is Influenced by 
Depletion of CD169+ Macrophages 
The diminished antibody responses in total IgG and IgG subtypes when 
comparing wild type mice to either CD169 knockout mice or low dose clodronate treated 
mice led us to hypothesize that low dose clodronate treatment and CD169 knockout were 
lessening the immune stimulating ability of adjuvants for antibody production. One 
imperative step for antibody production is the presence of antigen within the lymph nodes 
in order for the adaptive immune system to be initiated by either antigen presenting cells 
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(APCs) activating T follicular helper cells (Goenka et al., 2011; Lahoud et al., 2011) or 
antigen deposited on follicular dendritic cells for B cell receptor affinity maturation 
(Allen & Cyster, 2008; Nossal, Abbot, & Mitchell, 1968). We investigated the total 
amount of OVA present in the draining lymph nodes 24 hours post subcutaneous 
immunization with our OVA +/- adjuvant preparations. As shown in Figure 4.4, PorB 
was the only adjuvant to significantly increase OVA mean fluorescent intensity (MFI) in 
the lymph nodes as compared to OVA alone. Interestingly, a significantly decreased 
OVA MFI in low dose clodronate treated mice and CD169 knockout mice were observed 
with the use of PorB as an adjuvant when comparing to wild type mice. The MFI of OVA 
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Figure 4.4: MFI of OVA from iliac lymph nodes in Control B6, low dose 
clodronate Treatment and CD169 knockout animals
Figure 4.4: Mean Fluorescent Intensity (MFI) of Antigen (OVA-A594) in the Draining Lymph 
Node 24 Hours Post Subcutaneous Injection. 
Mean fluorescent intensity (MFI) of antigen (OVA) in draining lymph nodes 24 hours post vaccination of 
either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum. MFI of OVA was 
quantified by the ImageJ measurement tool after the subtraction of the background. Wild type control 
injections are shown in the bars with no pattern. Low dose clodronate treated animals are shown in the 
stripped bars. CD169 knockout animals are shown in checkered bars. n = 8-13. Statistics were calculated 
by ordinary one-way ANOVA with Sidak’s multiple comparisons test. *p<0.05, **p<0.01 
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was decreased with CpG as an adjuvant in only low dose clodronate when compared to 
wild type.  The use of Alum as an adjuvant in the CD169 KO mice also showed a 
significant decrease in OVA MFI from wildtype control. 
 
Follicular Dendritic Cell Networks are Influenced by Clodronate Treatment  
Although a decrease in antigen within the lymph nodes could explain a significant 
decrease in antibody production, it was also important to determine if depleting CD169 
macrophages by low dose clodronate treatment or removal of CD169 by using CD169 
KO mice could also influence the FDC network and antigen deposition on FDCs. These 
studies are derived from our previous studies demonstrating that PorB can greatly 
enhance both the FDC network and also increase antigen deposition on FDCs. In 
addition, it has been shown that SCS (CD169+) macrophages are important for entry of 
particulate matter into the follicle and germinal center to interact with APCs and FDCs. 
Figure 4.5A shows representative images of draining lymph nodes in all treatments and 
all immunization groups. FDC staining is shown as a heat map where the highest 
signal/pixel (px) ratio is shown as white and the lowest signal/px ratio is shown in blue. 
Similar to our previous work (see Chapter 3), only the use of TLR-ligand based adjuvants 
induced increased FDCs in the draining lymph node from immunized WT mice (top 
row). Interestingly, low dose clodronate treatment and removal of subcapsular 
macrophages diminished this increase similarly to unimmunized mice, which was not 
observed in the immunized CD169 knockout mice. The MFI of FDC was quantified by 
the measurement tool within ImageJ and the data are shown in Figure 4.5B.  The data is 
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consistent with the data in Figure 4.5A.  As a way to confirm these results, we analyzed 
the draining lymph node from flow cytometric analysis to compare the frequency 
percentages of FDCs in similar treated and immunized mice. The flow data was similar to 
the IHC and MFI measurements – immunizations including TLR-adjuvants significantly 
increased FDC frequencies in WT mice, but was diminished in low dose clodronate 
treated mice but not in CD169 KO mice (Figure 4.5C). 
Antigen Deposition on Follicular Dendritic Cells Induced by PorB is Decreased in 
Low Dose Clodronate Treated Mice and CD169 Knockout Mice 
 Since FDC frequency was decreased in clodronate treated animals as compared to 
wild type control, we investigated whether antigen (ovalbumin tagged with Alexa-594, 
OVA-594) deposition on FDCs, that we have previously seen to be increased with the use 
of PorB as an adjuvant, would be affected by removal of SCS macrophages by low dose 
clodronate treatment or in the CD169 KO mice. Consistent to previous studies done in 
our lab, PorB shows an increase of colocalization with FDC and antigen over vehicle 
control as shown by yellow arrows in Figure 4.6A. Interestingly, depletion of SCS 
macrophages and CD169 knockout animals showed a significant decrease of this 
colocalization as shown in Figure 4.6A and D. Immunizations including Alum as an 
adjuvant showed significant increases in the wildtype mice (Figure 4.6C and D). 
Surprisingly, immunizations with Alum in the CD169 knockout animals showed a slight 
decrease in colocalization between FDC and OVA (Figure 4.6C and D) from wild type 
animals. Vaccines that contained CpG showed no significant differences in colocalization 
between FDC and OVA in any of the animal models tested (Figure 4.6B and D). 
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Figure 4.5: Low Dose Clodronate Significantly Decreases FDC Networks After TLR-Ligand 
Based Adjuvants. 
(A) Representative images for FDC networks in draining lymph nodes 24 hours post OVA-A594 
subcutaneous injections and 48 hours post intravenous low dose clodronate injections. FDC expression is 
shown as a heat map where white indicates the highest signal to pixel ratio and blue sows the lowest signal 
to pixel ratio. Scale bar is 100 µM. One out of 2 representative experiments is shown. (B) Mean 
fluorescence intensity (MFI) quantification from ImageJ of FDC in draining lymph nodes 24 hours post 
injection of either OVA-A594, OVA-A594+PorB, OVA-A594+CpG, or OVA-A594+Alum in all three 
animal models. Wild type control injections are shown in the bars with no pattern. Low dose clodronate 
treated animals are shown in the stripped bars. CD169 knockout animals are shown in checkered bars. 
Multiple FDC networks were measured within the lymph nodes. n=7-15/group. (C) Frequency of FDC 
cells in draining lymph nodes 24 hours post subcutaneous injections with OVA-A594 +/- adjuvants. (n=6). 
Gating strategy is shown in supplemental figure 5. Statistics were calculated by ordinary one-way ANOVA 
with Sidak’s multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001 
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Figure 4.6D: Colocalization of FDC and OVA in Control B6, Low Dose clodronate 
Treatment and CD169 knockout animals
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Figure 4.6: Low Dose Clodronate and CD169 Knockout Animals Decrease Antigen Deposition 
onto FDCs. 
Representative immunohistochemistry images from draining lymph nodes from wildtype, clodronate 
treated mice, and CD169 knockout mice 24 hour post subcutaneous injections of PorB (A), CpG (B), or 
Alum (C) and 48 hours post clodronate treatment. FDC is shown in green. OVA-A594, used as a non-
immunogenic antigen, is shown in red. Images were taken at 63x objective using a Leica SP5 microscope. 
Areas of co-localization are shown with yellow arrows. Scale bar represents 20µM. One out of 6 
representative experiments is shown. (D) Quantification of colocalization between fluorescently labeled 
OVA-A594 with FDC within draining lymph nodes 24 hours post subcutaneous injections. Colocalization 
was assessed using Pearson Correlation coefficients calculated within JaCoP plugin in ImageJ after 
background subtraction and unsharp mask filter. n=8-12/group. Wild type control injections are shown in 
the bars with no pattern. Low dose clodronate treated animals are shown in the stripped bars. CD169 
knockout animals are shown in checkered bars. Statistics were calculated by ordinary one-way ANOVA 
with Sidak’s multiple comparisons test. *p<0.05, **p<0.01, ***p<0.001 ****p<0.0001 
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OVA Association with DCs and FDCs is Influenced by Depletion of SCS 
Macrophages 
To determine the distribution of antigen, Mander’s correlation coefficients were 
determined via JaCoP. This correlation coefficient allows for spilt channels of correlation 
to be determined (Bolte & Cordelieres, 2006) as percentages. The percentages of OVA 
correlated with either DCs or FDC were then multiplied by the MFI of OVA (Figure 4.4) 
to determine the MFI of OVA associated with DCs, FDC, or unassociated. We defined 
“unassociated OVA” as the remaining percentage of OVA that was not associated with 
either DC or FDC (Unassociated OVA = 1-[Mander’s coefficient for OVA/DC + 
Mander’s coefficient for OVA/FDC]). There are, however, other cell types within the 
lymph node during this time with which OVA could associate (B cells or macrophages), 
though unlikely. For the purpose of these studies, however, these cell types are included 
in the “unassociated” section because of the importance of antigen loaded DCs and 
antigen deposited on the FDCs at early timepoints for induction of an adaptive immune 
response. All adjuvanted immunizations induced some increase in OVA associated DCs 
when compared to vehicle control, however consistent with our previous data (Reiser et 
al., 2017), PorB induced the greatest association (Figure 4.7A) from other adjuvants and 
vehicle control. In both low dose clodronate treated mice and CD169 KO mice 
immunized with OVA + PorB, there was significant decreases in DC/OVA (Figure 4.7A) 
and FDC/OVA correlation coefficients (Figure 4.7B) when compared to wild type treated 
mice. Unassociated OVA in both low dose clodronate and CD169 knockout animals had 
a significant increase over WT mice in these PorB/OVA mice (Figure 4.7C). CpG/OVA 
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immunized mice only showed significant differences in DC/OVA correlation in 
clodronate treated animals (Figure 4.7A) while comparing to the wild type group. No 
differences were seen with CpG/OVA immunizations in low dose clodronate treated mice 
or CD169 KO mice in FDC/OVA (Figure 4.7B). Alum usage showed a significant 
decrease in both DC/OVA (Figure 4.7A) and FDC/OVA in CD169 KO mice (Figure 
4.7B) when compared to wild type groups, but had no difference in low dose clodronate 
treated mice.  Overall, the increases of OVA association with FDCs or DCs was always 
greater in mice receiving PorB/OVA, and the decrease in the low dose clodronate treated 
mice or CD169KO mice were subsequently greater when PorB/OVA was used as 
opposed to CpG/OVA or Alum/OVA. 
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Figure 4.7: OVA-A594 Distribution Lymph Node Between DC, FDC, and Unassociated OVA. 
MFI of OVA associated with DC (A), FDC (B), or unassociated OVA (C) was assessed using the JaCoP 
plugin within ImageJ and determining the Mander’s correlation coefficient after subtracting the 
background and using an unsharp mask filter. The correlation coefficient is the percentage of OVA 
associated with either FDCs or DCs. This percentage was then multiplied by the total MFI of OVA within 
the lymph node (Figure 2) to determine MFI of OVA associated with DCs or FDCs. These data were 
assessed in draining lymph nodes 24 hours post injection of either OVA-A594, OVA-A594+PorB, OVA-
A594+CpG, or OVA-A594+Alum in all three animal models. Wild type control injections are shown in 
the bars with no pattern. Low dose clodronate treated animals are shown in the stripped bars. CD169 
knockout animals are shown in checkered bars. Statistics were calculated by ordinary one-way ANOVA 
with Sidak’s multiple comparisons test. n= 5-7 *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
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Wildtype	Control	(B6)	 PorB	 CpG	 Alum	Total	Antigen	Specific	IgG	 **	 **	 ***	Antigen	in	SLO	 ***	 --	 --	FDC	Network	Quantification	 ***	 ***	 --	Antigen	Deposition	onto	FDCs	 ****	 --	 ***	Antigen	Associate	with	DCs	 ****	 *	 **	
 
Table 1: Results of how adjuvants influence antibody production, antigen distribution, and FDC 
networks.  
Wildtype (C57/B6L) animals were vaccinated with an antigen (OVA) plus or minus adjuvants. The 
adjuvants used were either PorB, CpG, or Alum. Vaccines including PorB had significant increases in total 
antigen specific IgGs, antigen present within the draining lymph node, FDC networks, antigen deposition 
onto FDCs and antigen associate with DCs when compared to OVA alone vaccinations. Vaccines including 
CpG had significant increases in total antigen specific IgGs, FDC networks, and antigen associate with DCs 
when compared to OVA alone vaccinations. Vaccines including Alum had significant increases in total 
antigen specific IgGs, antigen deposition onto FDCs and antigen associate with DCs when compared to 
OVA alone vaccinations. Statistics were calculated by ordinary one-way ANOVA with Sidak’s multiple 
comparisons test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 		 	
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Low	Dose	Clodronate	 PorB	 CpG	 Alum	Total	Antigen	Specific	IgG	 **	 *	 *	Antigen	in	SLO	 **	 *	 --	FDC	Network	Quantification	 ***	 **	 --	Antigen	Deposition	onto	FDCs	 **	 --	 --	Antigen	Associate	with	DCs	 ****	 *	 --		
Table 2: Results of how low dose clodronate treatment effects adjuvanticity for antibody 
production, antigen distribution, and FDC networks. 
Wildtype (C57/B6L) animals received a low dose of clodronate intravenously 24 hours prior to vaccination. 
Vaccinations included antigen (OVA) plus or minus an adjuvant. The adjuvants used were either PorB, 
CpG, or Alum. Vaccines including PorB had significant decreases in total antigen specific IgGs, antigen 
present within the draining lymph node, FDC networks, antigen deposition onto FDCs and antigen 
associate with DCs when compared to wildtype control animals. Vaccines including CpG had significant 
decreases in total antigen specific IgGs, antigen within the draining lymph node, FDC networks, and 
antigen associate with DCs when compared to wildtype control animals. Vaccines including Alum had 
significant decreases in total antigen specific IgGs when compared to wildtype control animals. Statistics 
were calculated by ordinary one-way ANOVA with Sidak’s multiple comparisons test. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 	  
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CD169	Knockout		 PorB	 CpG	 Alum	Total	Antigen	Specific	IgG	 **	 **	 *	Antigen	in	SLO	 **	 --	 **	FDC	Network	Quantification	 --	 --	 --	Antigen	Deposition	onto	FDCs	 *	 --	 *	Antigen	Associate	with	DCs	 ****	 --	 ****	
 
Table 3: Results of how CD169 global knockout effects adjuvanticity for antibody production, 
antigen distribution, and FDC networks. 
CD169 knockout animals received vaccines which consisted of antigen (OVA) plus or minus an adjuvant. 
The adjuvants used were either PorB, CpG, or Alum. Vaccines including PorB had significant decreases in 
total antigen specific IgGs, antigen present within the draining lymph node, antigen deposition onto FDCs 
and antigen associate with DCs when compared to wildtype control animals. Vaccines including CpG had 
significant decreases in total antigen specific IgGs when compared to wildtype control animals. Vaccines 
including Alum had significant decreases in total antigen specific IgGs, antigen present within the draining 
lymph node, antigen deposition onto FDCs and antigen associate with DCs when compared to wildtype 
control animals. Statistics were calculated by ordinary one-way ANOVA with Sidak’s multiple 
comparisons test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
	
Discussion 
In order to further characterize cellular mechanisms of adjuvant activity within 
the lymph node and germinal center, we utilized two animal models which interrogate the 
subcapsular macrophage population in these structures. We choose to target this cell type 
for two reasons. Firstly, our lab has previously determined that a defect in TLR signaling, 
by genetic depletion of MyD88, specifically in macrophages greatly diminished the 
adjuvant effect of PorB, as shown by significantly decreased antibody production (M. M. 
Mosaheb et al., 2017). Unexpectedly, no other APC could rescue the depleted antibody 
production from animals with MyD88 genetically removed from macrophages. These 
data led us to focus on our studies on macrophage subtypes specifically. Secondly, Cyster 
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et al. have shown SCS macrophages to be imperative for antigen transport and deposition 
on FDC (Tri Giang Phan et al., 2009) and we have recently shown that PorB can greatly 
enhance this process. The two variants of mice we used for these studies were 1) mice 
treated with low dose clodronate which has been shown to cause apoptosis and removal 
solely of SCS macrophages (T. L. McGaha et al., 2011) and 2) CD169 knock out mice. It 
is important to note that while clodronate treatment cause a depletion of a SCS 
macrophages, these cells will still be present in the CD169 knockout animals although 
without the CD169 molecule. Immunization with adjuvanted vaccines of both types of 
mice demonstrated a decreased total antigen-specific antibody response as compared to 
wild type mice. Importantly, the use of TLR-ligand based adjuvants, CpG and most 
significantly, PorB, had a much more dramatic decrease compared to the use of Alum 
(Figure 4.3A) when compared to wild type groups receiving the same vaccine 
composition. We investigated IgG subtypes in order to determine if loss of SCS 
macrophages or CD169 would have any influence on Th1 or Th2 adaptive immune 
responses to adjuvant vaccine regimes. Alum vaccine injections almost exclusively 
induced IgG1 (as expected, when compared to vehicle control) and this was unaffected in 
low dose clodronate treated mice and CD169 KO mice (Figure 4.3B), suggesting IgG1 
antibody production is not dependent on SCS macrophages with Alum injections. In 
contrast, when PorB was used as an adjuvant, OVA-specific IgG1 showed a significant 
decrease in both clodronate treated and CD169 KO mice as compared to WT mice 
(Figure 4.3B).  The use of CpG as an adjuvant did not induce detectable levels of OVA-
specific IgG1 compared to vehicle control. Both TLR-ligand based adjuvants, PorB and 
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CpG, induced OVA-specific IgG2c levels from vehicle control which were significantly 
decreased in clodronate treated and CD169 KO mice as compared to WT mice (Figure 
4.3C). These data emphasize that TLR-ligand based adjuvants likely utilize SCS 
macrophages to a much greater extent than Alum for their adjuvant effect. This is 
consistent with our MyD88 conditional KO data, as TLR2 and TLR9 both require 
MyD88 for signaling. To confirm the role of MyD88 in the adjuvant effect of PorB and 
CpG on these SCS and marginal zone macrophages, we can produce MyD88 conditional 
KOs in these CD169+ cells utilizing MyD88-floxed mice and CD169-cre-recombinase 
mice. These studies are currently on going as the CD169-cre mice have only recently 
become available. 
As part of these studies, we investigated the potential association of SCS 
macrophages in relation to the use of adjuvants and early immune processes involved in 
B cell receptor affinity maturation and somatic hypermutation, which lead to antibody 
production. These studies namely investigated the quality of FDCs and the ability of 
adjuvants to enhance intact deposition on these FDCs. We have recently shown that PorB 
can increase intact OVA deposition on FDCs (chapter 3) and in these new experiments 
described here-in, will now examine if the lack of SCS macrophages or the lack of 
CD169 expression could affect this process utilizing low dose clodronate treated mice, 
and CD169 KO mice. These analyses support that the adjuvants tested here (PorB, CpG, 
and Alum) utilize SCS macrophages by different mechanisms. Animals immunized with 
OVA + PorB seem to be the most affected by loss of either marginal zone macrophages 
or the global loss of CD169; total antigen (Figure 4.4) and antigen deposition on FDCs 
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(Figure 4.6A and D) were significantly decreased in both sets of mice as compared to WT 
mice. In combination, this could be the reason that OVA specific IgG production in these 
mice when immunized with PorB/OVA was significantly diminished from wild type 
control animals (Figure 4.3). These data also suggest that the adjuvant activity of PorB 
may be more dependent on SCS macrophages for enhancing antibody production versus 
CpG or Alum considering the decrease in responses occurred in both low dose clodronate 
treatment and CD169 knockout animals. One explanation for this would be the native 
structure of PorB, which we have described previously (Massari et al., 2005; Yuen et al., 
2019). The porin is used in the form of proteasomes, or pure protein micelles and likely 
preserve the native trimeric structure of PorB, and is similar to other particles that have 
been shown to influence SCS macrophages. Saunderson et al. have shown that exosomes 
are retained in the SCS macrophages and global CD169 knockout animal models (mice 
which do not express CD169 molecules) allowed for penetration of exosomes to the 
paracortex of the lymph node (Saunderson, Dunn, Crocker, & McLellan, 2014). It is 
possible that PorB is stimulating the marginal zone macrophages more that CpG or Alum 
based on PorB’s structure leading to the increase of antigen within the lymph node and 
FDC deposition in wildtype mice that is abated in low dose clodronate and CD169 
knockout mice. Follow up studies looking at how PorB increases TLR expression on SCS 
as well as studies with CD169-cre and MyD88 floxed animals would clarify the role of 
TLR signaling in these pathways. 
Immunizations containing CpG showed significant increases in total OVA-
specific IgGs as well as OVA-specific IgG2c from vehicle control groups (Figure 4.3). 
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Similarly to PorB, clodronate treatment and CD169 KO animals showed significant 
decreases in antibody concentrations from wild type animals. Based on the early immune 
responses measured in this study, however, the mechanism of action for CpG to describe 
the decrease of antibodies may be different than that of PorB. CpG vaccines showed a 
significant increase in FDC networks in wildtype mice from vehicle control (Figure 4.5), 
but showed no significant increase in antigen deposition onto FDCs (Figure 4.6) when 
comparing to vehicle control. FDC networks were significantly decreased in animals who 
received clodronate treatments prior to vaccines containing CpG compared to wild type 
animals. There is the possibility that clodronate is having a direct effect on the FDCs, 
which has not been shown before, as PorB injected animals also had a significant 
decrease in FDCs when compared to wildtype control animals. Another interesting result 
was how clodronate treatments influenced OVA association with DCs in animals 
vaccinated with CpG. When comparing clodronate treated animals who received CpG 
vaccinations to wildtype animals who received CpG vaccinations, OVA/DC association 
was significantly decreased when compared to the wild type group. This may be due to 
less OVA present within the draining lymph node (Figure 4.4). Taken together, a 
decrease in FDC networks in combination with decreased DC/OVA association when 
compared to wild type groups, could be a major reason for the significant decreases 
shown in antibody production. With less antigen loaded DCs present in the draining 
lymph node, Tfh cells would not be activated as antigen loaded DCs are the primary cell 
to activate Tfh during an immune response. In concert, a decrease in FDC networks 
would lead to less surface area for free antigen to be deposited for B cell receptor affinity 
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to occur. Therefore, decreased Tfh activation and less opportunity for BCR affinity 
maturation would decrease antibody production.  
 Aluminum salts (Alum) were included to determine if adjuvants which do not 
signal through TLRs may have varying cellular mechanisms of induction of antibody 
production as compared to TLR-ligand based adjuvants. Total antigen specific IgG was 
significantly decreased in both low dose clodronate treated and CD169 knockout animals 
when compared to wildtype controls (Figure 4.3A) for OVA + Alum immunized animals. 
These decreases, however, were not as significant as the decrease in TLR-ligand based 
adjuvants, PorB and CpG. Interestingly, IgG1 subtype levels were similar in these mice 
as compared to WT mice when Alum was used as an adjuvant (Figure 4.3B). While 
investigating innate immune responses to determine if SCS macrophages or CD169 
knockout animals influenced Alum vaccinations, we have found that less antigen is 
present in the draining lymph nodes of CD169 knockout animals when compared to 
wildtype (Figure 4.4).  The lack of antigen present can elucidate the decrease in antigen 
deposition onto FDC (Figure 4.6C and D, Figure 4.7B) as well as the decrease in OVA 
associated with DC (Figure 4.7A) when compared to wild type control groups. Together 
these data suggest that Alum requires expression of CD169 molecule for antigen to enter 
the draining lymph node. There are CD169+ DCs within the lymph node (Gerner et al., 
2015). It is possible that Alum utilizes this DC population, and not the SCS macrophages, 
for antibody production explaining the decrease we saw in CD169 knockout animals 
from control groups but no significant changes in the low dose clodronate treated groups.  
In conclusion, in examining the possible role of subcapsular sinus macrophages 
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and/or the expression of CD169 on these cells, we have found that these alterations affect 
the adjuvant effect of PorB, CpG and Alum in varying degrees. Interestingly, TLR-ligand 
based adjuvants had a more dramatic decrease than that of Alum immunizations on 
antibody production when comparing to wild type animals. Investigating antigen within 
the draining lymph node, as well FDC and DC cellular association of antigen, concluded 
all three adjuvants working through different cellular interactions. The most dramatic 
decreases in antigen specific antibody in both clodronate treated and CD169 knockout 
mice occurred when PorB was used as an adjuvant, leading us to hypothesize that the 
extracellular TLR1/2 agonist utilizes the SCS macrophages more than the other adjuvants 
tested here. Since SCS macrophages have been shown to be pivotal for antibody 
production (Veninga et al., 2015), we believe these data support that PorB has unique 
characteristics, such as the ability to stimulate both Th1 and Th2 antibody responses and 
the trimeric structure of the adjuvant, that make PorB a higher quality adjuvant than 
others.   	 	
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Conclusion 
Summary of Results 
In the Chapter 3 of this thesis, we investigated how the TLR-ligand based 
adjuvant, PorB, influenced FDC networks and antigen deposition on to FDCs, which can 
explain one mechanism or PorB’s ability to increase antigen specific antibodies. We 
found that PorB was able to increase antigen presence in draining lymph nodes 24 hours 
post subcutaneous injection when compared to vehicle control. TLR-ligand based 
adjuvants showed a significant increase in FDC networks, yet only PorB showed a 
significant increase in antigen deposition on FDCs over vehicle control. Alum 
vaccinations also showed a significant increase in antigen deposition on FDCs from 
vehicle control, but did not show an increase in FDC networks. The antigen deposition on 
FDC networks was determined to not be due to overlap of antigen loaded DCs. 
Interestingly, PorB alone showed a significant increase in both antigen loaded DCs and 
antigen deposition on to FDCs from vehicle control and other adjuvants. PorB also 
showed the only significant decreases in unassociated OVA within the draining lymph 
node from vehicle control. Therefore, in the analyzes investigated for this thesis, PorB 
showed superior characteristics when compared to another TLR-ligand based adjuvant 
and a non-TLR-ligand based adjuvant.  
 Chapter 4 of this thesis focused on the role of SCS macrophages in antibody 
production induced by adjuvant containing preparations and how the presence or absence 
of these cells would affect innate immune responses leading to adaptive immune system 
activation. We investigated the role of these macrophages because of previous studies in 
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our laboratory that showed MyD88 signaling within macrophages to be imperative for 
antibody production which no other cell type could rescue. We utilized two animal 
models to investigate the SCS macrophages – a low dose clodronate intravenous injection 
and a CD169 global knockout animal. We showed that low dose clodronate and CD169 
knockout animals had significant decreased of antigen-specific total IgG from wild type 
groups regardless of adjuvant used. Interestingly, only TLR-ligand based adjuvants 
demonstrated a significant decrease in antigen-specific IgG subtypes from wild type 
groups. To further examine the cellular kinetics of the effect of the absence of CD169+ or 
SCS macrophages on antibody production, we investigated the distribution of antigen 
within the draining lymph of animals after low dose clodronate treatment or CD169 
knockout animals. Animals vaccinated with PorB as an adjuvant showed significant 
decrease in antigen presence in draining lymph nodes when SCS macrophages were 
depleted as well as CD169 knockout animals compared to wild type groups. The lack of 
antigen present within the lymph nodes led to decrease antigen deposition onto FDCs and 
antigen loaded DCs in clodronate treated animals and CD169 knockout animals when 
compared to wildtype controls. When CpG or PorB were used as adjuvants, there was a 
significant decrease in antigen associated with DCs in clodronate treated animals 
compared to wild type groups. Alum vaccinations showed a significant decrease of 
antigen presence in draining lymph nodes of CD169 knockout mice compared to wild 
type groups. This lack of antigen explains the significant decrease in antigen deposited 
onto FDCs and DCs associated with antigen within draining lymph nodes in CD169 
knockout animals. These data emphasize how adjuvants can utilize different cellular 
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interactions to generate an adaptive immune response. From these data, we also draw to 
the conclusion, that PorB exploits SCS macrophages more than other adjuvants tested 
here. Depletion of SCS macrophages via low dose clodronate treatment and global 
knockout of CD169 led to significant decrease in antibody production, antigen 
association with DCs, and antigen deposition onto FDCs.  
Future Directions  
 A majority of this project has been investigating how PorB, when used as a 
vaccine adjuvant, is able influence early adaptive immune responses which lead to 
increase antibody production. We were also able to determine the role of a subset of 
macrophages, subcapsular sinus (SCS) macrophages, not only antibody production, but 
also antigen deposition onto follicular dendritic cells and antigen loaded DCs. While 
these studies progress the vaccine adjuvant field, there are still studies we would like to 
explore in the future. They are listed as followed:  
1. Determine how vaccinations, including PorB as an adjuvant, influence cytokine 
and chemokine expression within the draining lymph node. We have previously 
shown how injections including PorB influence systemic cytokine expression 
within the sera of animals (M. Mosaheb & Wetzler, 2018). However, it is 
reasonable that cytokine and chemokine expression within the microenvironment 
of the lymph node would differ from that of systemic sera. It would also be 
interesting to investigate how the chemokine and cytokine levels within draining 
lymph nodes vary in animals treated with clodronate and CD169 knockout 
animals after receiving a PorB injection. We have shown in chapter 4 of this 
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thesis that antibody production is decreased in animals that received clodronate 
treatments and CD169 knockout animals. Determining how cytokine and 
chemokine levels differ in draining lymph nodes post PorB injection could be 
incredibly useful for future vaccination development.  
2. As mentioned in the discussion of chapter 4, determining the role of MyD88 
signaling specifically in SCS macrophages would be critical to elucidated the 
signaling pathways describe PorB’s superior adjuvanticity. Our laboratory has 
shown that MyD88 signaling within macrophages is necessary for antibody 
production and cannot be rescued by DCs or B cells (M. M. Mosaheb et al., 
2017). Here we show that depletion of SCS macrophages or CD169 knockout led 
to a significant decrease in antigen-specific total IgG. To further examine the 
cellular interactions and mechanistic signaling within the lymph node that leads to 
antibody production, MyD88 floxed animals would be bred with CD169 cre 
animals. This breeding pair would led to impaired MyD88 signaling within 
CD169+ cells specifically. An IACUC protocol has been written for these animals 
in order to start the studies as soon as possible.  
3. Determine TLR (especially TLR2) expression on SCS macrophages and whether 
PorB may affect this. Subcapsular sinus macrophages have been shown to be 
important for induction of immune responses (Delemarre et al., 1990; Junt et al., 
2007; Tri Giang Phan et al., 2009). To date, there have been no studies to 
determine if adjuvants influence TLR expression on or within the endosomal 
compartment of SCS macrophages. These studies would provide insight on how 
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TLR expression on SCS influences immune responses especially antibody 
production.  
4. Determine how PorB induction of antigen specific antibody production leads to 
IC formation after multiple injections. An initial study for this future direction 
was performed in chapter 3 of this thesis and utilized different fluorochromes to 
determine if the antigen was from the first injection or second. A majority of 
studies looking at antigen deposition on FDCs have focused on passive 
immunizations with IC. Our future directions would differ from this by utilizing 
sera of animals that have previously been injected, either after the first booster or 
after the second, to determine the extent of IC formation and how that influences 
antigen deposition onto the FDCs.  
Our laboratory has focused on the TLR2/1-ligand based adjuvant, PorB, and the 
major characteristics of this adjuvant allowing for influence on both the innate and 
adaptive immune responses. The studies presented in this thesis were done to investigate 
how the innate immune system within the microenvironment of the lymph node is guides 
the adaptive responses. In the future, the interactions between innate and adaptive 
responses will need to be further investigated in order to fully understand the cellular 
mechanisms of PorB.  
Significance  
These studies were designed to compare PorB induced antibody production in 
comparison to other vaccine adjuvants, either TLR-mediated (CpG) or non (Alum) in 
correlation to the effect of the adjuvants on antigen association with FDCs and the 
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potential role of CD169+ SCS macrophages. We found that TLR-ligand based adjuvants 
showed a significant increase in FDC networks 24 hours post injection in the draining 
lymph nodes. As depicted in chapter 3, an increase in FDC networks allows for more 
antigen to be deposited during affinity maturation of the B cell receptor of B cells. An 
increased of surface area for antigen deposition would allow for more BCR/antigen 
interactions and, in theory, allow for a quicker affinity maturation. The increase of FDC 
networks with TLR-ligand based adjuvants has not been identified prior to our studies. 
Further, our studies showed that PorB and Alum increased antigen deposition on to FDC 
networks for the first time. Antigen deposition on FDCs is a critical step for affinity 
maturation and a desired characteristic of an adjuvant. In these studies, only PorB showed 
an increase in both FDC networks and antigen deposition onto FDCs. We also confirmed 
earlier studies from our lab that PorB increases antigen loaded DC in the draining lymph. 
Antigen loaded DCs are pivotal for T follicular helper cell activation by exposing the T 
cell to antigen peptide, providing costimulatory factors, and cytokine secretion. Together, 
an increase in FDCs (and therefore more surface area for antigen to be deposited on), 
antigen deposition onto FDCs, and antigen loaded DC, could describe how PorB has a 
broader antibody response than other adjuvants tested. These three cellular interactions 
are known for the classical responses for the germinal center formation leading to 
antibody production. If other adjuvants are able to stimulate these pathways similarly to 
PorB still remains to be known. These conclusions can give further insight to vaccine 
development.  
We also concluded, for the first time, that TLR-ligand based adjuvants have a 
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more significant decrease in antibody production with depletion of SCS macrophages or 
CD169 knockout compared to Alum. We also determined that low dose clodronate 
treatment and removal of CD169 macrophages was associated with a significant decrease 
of FDC networks in animals that received TLR-ligand based adjuvants (which has been 
shown to increase the size of these networks). This decrease may be due to a direct effect 
on the FDC network, although no significant decreases were seen in animals that received 
Alum vaccinations and clodronate treatments. The results of these studies confirmed prior 
results that different adjuvants utilize specific cellular mechanisms and interactions of the 
innate immune system. Our studies did emphasize, however, that PorB may exploit the 
SCS macrophage more than other adjuvants tested here. PorB vaccinated animals that 
received clodronate or were CD169 knockout had significant decreases in antigen within 
the draining lymph node, significant decreases in antigen loaded DCs, and significant 
decreases in antigen deposition on FDCs. These results are the first time that PorB has 
shown to have superior adjuvant characteristics focusing specifically on the SCS 
macrophages.  
With the field of vaccine development always progressing forward, it is important 
for adjuvants to be compared within a study to remove biases or focus of one adjuvant. 
The studies presented in this thesis do just that – we compared TLR-ligand based 
adjuvants, both intracellular and extracellular, to non-TLR-ligand based adjuvants in 
vivo. These studies also contributed to the immunology field by investigating innate and 
adaptive immune responses after the depletion of SCS macrophages or CD169 global 
knockout. Together these data further the immunology field and vaccine development. 
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APPENDIX 
A.1 CD169+ Macrophages Increase with PorB Injections 
  
Subcapsular CD169+ macrophages have been shown to be vital in multiple 
adaptive immune responses (Ludewig & Cervantes-Barragan, 2011; Tri Giang Phan et 
al., 2009; T. G. Phan et al., 2007). To date, no studies have shown if adjuvants can 
increase this important population of cells. Here we show that PorB significantly 
increases the subcapsular CD169+ macrophages over OVA alone two and three days after 
subcutaneous injection.  
A.	
B.	
A 1: CD169+ Macrophages are Increased with PorB Injections. 
Mice were immunized with OVA, OVA + PorB, or OVA +CpG. Draining lymph nodes were isolated and 
prepared in a single cell suspension for flow cytometry. PorB was the only adjuvant to significantly 
increase CD169+ macrophages by both frequency (A) and counts (B). Statistics for significance were 
calculated based on a Two-way ANOVA with Sidak’s multiple comparisons test for significance levels. 
n=3/group. *p<0.05, **p<0.01, 
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A.2 Cytokine Expression from Combinational Adjuvants 
	
  
 
 
 
 
 
TLR-ligand based adjuvants have become a cornerstone for subunit vaccines 
because of their ability to skew adaptive immune responses. (Beutler, 2009; Moyle & 
Toth, 2013). Recent studies have begun testing combinational TLR-ligand based 
adjuvants in order to further understand the connection between innate immune 
A.	 B.	
A 2: TLR-Ligand Based Adjuvants, in Combination, Increase Cytokine Expression in BMDCs. 
BMDCs (5 x 105) were stimulated in 24 well plates with either media (CTRL), ovalbumin (OVA), OVA + 
PorB, OVA + Poly(I:C), or OVA + PorB + Poly(I:C) for 24 hours. The supernatants from the cells were 
then analyzed for IL-6 (A), TNF-a (B), or IFNß (C) by ELISAs. Statistics for cytokine production were 
calculated based on a Two-way ANOVA with Sidak’s multiple comparisons test for significance levels. 
n=3/group. *p<0.05, **p<0.01, ****p<0.0001 
 
C.	
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stimulation and adaptive responses (Napolitani, Rinaldi, Bertoni, Sallusto, & 
Lanzavecchia, 2005; Weir et al., 2017). Here we investigated if PorB, an extracellular 
TLR2-ligand based adjuvant, and Poly(I:C), an intracellular TLR3-ligand based adjuvant, 
in combination would have higher cytokine expression than either adjuvant alone.  
The cytokines we investigated were chosen based on their ability to influence adaptive 
responses, a key characteristic desired by adjuvants. Interleukin 6 (IL-6) expression has 
been shown to induce maturation of B cells (Muraguchi et al., 1988) and cause 
differentiation of CD4+ and CD8+ T cells into specific subsets for protection (Diehl, 
Schmidlin, Nagasawa, Blom, & Spits, 2012; Yang et al., 2016).  Expression of tumor 
necrosis factor alpha (TNF-a) is a critical step for normal B cell development and 
survival (Shulga-Morskaya et al., 2004). Lastly, interferon beta (IFN-ß) has been shown 
to stimulate CD4+ T cells, which once activated, produced IL-4, IL-5, and IL-10, 
cytokines that have been shown to skew the adaptive response (Kadowaki, Antonenko, 
Lau, & Liu, 2000).  
As shown in Figure A 2, OVA + PorB and OVA + PorB + Poly(I:C) had a significant 
increase in expression of IL6 (A) and TNF-a (B) over OVA alone in BMDCs. 
Interestingly, OVA + PorB + Poly(I:C) had significant increases from OVA + PorB in 
both cytokines supporting the hypothesis that synergy for cytokine expression may occur 
with multiple TLR-ligand based adjuvant stimulation. Expectedly, IFN-ß expression was 
significantly increased with TLR3-ligand based adjuvant, Poly(I:C) (Figure A 2C). 
Surprisingly, there was no additional increase in IFN-ß expression with the addition of 
PorB.  
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